

Balanced Dispensing Limits (DL)



BlueCross BlueShield
of Oklahoma

Drug dispensing limits help encourage medication use as intended by the FDA.

Coverage limits are placed on medications in certain drug categories.

Limits may include:

- Quantity of covered medication per prescription
- Quantity of covered medication in a given time period

If your doctor prescribes a greater quantity of medication than what the dispensing limit allows, you can still get the medication. However, you will be responsible for the full cost of the prescription beyond what your coverage allows.

The following brand drugs, and their generic equivalents, if available, have dispensing limits. Some of these dispensing limits may not apply to all members or may vary based on state regulations. Some dispensing limits listed below may apply across multiple medications within a drug class. Some plans may exclude coverage for certain agents or drug categories, like those used for erectile dysfunction (example: Viagra). Some drugs may not be available through mail service. Coverage for some drug categories, such as specialty or other select non-specialty medications, may be limited to a 30-day supply at a time depending on your particular benefit plan. Please see your plan materials or call the number on the back of your ID card to verify if you are uncertain of any plan limitations or exclusions. This list is subject to change.

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| abacavir 20 mg/mL oral solution (Ziagen) | 960 mL per 30 days | BG |
| abacavir 300 mg tablet (Ziagen) | 60 tablets per 30 days | BG |
| abacavir/lamivudine 300-600 mg tablet (Epzicom) | 30 tablets per 30 days | BG |
| abacavir-dolutegravir-lamivudine 600-50-300 mg tablet (Triumeq) | 30 tablets per 30 days | B |
| abacavir-lamivudine-zidovudine 300-150-300 mg tablet (Trizivir) | 60 tablets per 30 days | BG |
| abaloparatide 3120 mcg/1.56 mLs injection (Tymlos) | 1 injection per 30 days | B |
| abatacept 125 mg/mL syringe, autoinjector (Orencia ClickJect) | 4 syringes per 28 days | B |
| abatacept 125 mg/mL syringe, pre-filled (Orencia) | 4 syringes per 28 days | B |
| abatacept 50 mg/0.4 mL syringe, pre-filled (Orencia) | 4 syringes per 28 days (1.6 mLs = 4 syringes = 1 box) | B |
| abatacept 87.5 mg/0.7 mL syringe, pre-filled (Orencia) | 4 syringes per 28 days (2.8 mLs = 4 syringes = 1 box) | B |
| acclidinium 400 mcg/actuation oral inhaler (Tudorza Pressair) | 1 inhaler per 30 days | B |
| adalimumab 10 mg/0.1 mL prefilled syringe (Humira) | 2 syringes per 28 days | B |
| adalimumab 10 mg/0.2 mL syringe (Humira) | 2 syringes per 28 days | B |
| adalimumab 20 mg/0.2 mL prefilled syringe (Humira) | 2 syringes per 28 days | B |
| adalimumab 20 mg/0.4 mL syringe, kit (Humira) | 2 syringes per 28 days | B |
| adalimumab 40 mg/0.4 mL prefilled syringe (Humira) | 2 syringes per 28 days | B |
| adalimumab 40 mg/0.8 mL pen, Crohn's Disease, Ulcerative Colitis, or Hidradenitis Starter Kit (Humira) | 1 kit per 180 days | B |
| adalimumab 40 mg/0.8 mL pen, kit (Humira) | 2 pens per 28 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| adalimumab 40 mg/0.8 mL pen, Psoriasis/Uveitis Starter Kit (Humira) | 1 kit per 180 days | B |
| adalimumab 40 mg/0.8 mL syringe, kit (Humira) | 2 syringes per 28 days | B |
| adalimumab 40 mg/0.8 mL syringe, Pediatric Crohn's Disease Starter Kit (Humira) | 1 kit per 180 days (3 syringes = 1 kit) | B |
| adalimumab 40 mg/0.8 mL syringe, Pediatric Crohn's Disease Starter Kit (Humira) | 1 kit per 180 days (6 syringes = 1 kit) | B |
| adalimumab 80 mg/0.8 mL & 40 mg/0.4 mL pen, Psoriasis/Uveitis Starter Kit (Humira) | 1 kit per 180 days | B |
| adalimumab 80 mg/0.8 mL & 40 mg/0.4 mL syringe, Pediatric Crohn's Disease Starter Kit (Humira) | 1 kit per 180 days (2 syringes = 1 kit) | B |
| adalimumab 80 mg/0.8 mL syringe, Pediatric Crohn's Disease Starter Kit (Humira) | 1 kit per 180 days (3 syringes = 1 kit) | B |
| adalimumab 80 mg/0.8 mL pen, Crohn's Disease, Ulcerative Colitis, or Hidradenitis Starter Kit (Humira) | 1 kit per 180 days | B |
| albiglutide 30 mg/dose prefilled pen powder for injection (Tanzeum) | 4 pens per 28 days | B |
| albiglutide 50 mg/dose prefilled pen powder for injection (Tanzeum) | 4 pens per 28 days | B |
| albuterol sulfate 0.083% solution for nebulization (albuterol sulfate) | 375 mL per 30 days | BG |
| albuterol sulfate 0.5% solution for nebulization (albuterol sulfate) | 60 mL per 30 days | BG |
| albuterol sulfate 0.5% solution for nebulization (albuterol sulfate) | 60 mL per Rx | BG |
| albuterol sulfate 0.63 mg/3 mL solution for nebulization (AccuNeb) | 375 mL per 30 days (QL cumulative across strengths) | G |
| albuterol sulfate 1.25 mg/3 mL solution for nebulization (AccuNeb) | 375 mL per 30 days (QL cumulative across strengths) | G |
| albuterol sulfate 90 mcg/actuation oral inhaler (ProAir HFA) | 2 inhalers per 30 days (17 g = 2 inhalers = 400 doses) | B |
| albuterol sulfate 90 mcg/actuation oral inhaler (ProAir RespiClick) | 2 inhalers per 30 days | B |
| albuterol sulfate 90 mcg/actuation oral inhaler (Proventil HFA) | 2 inhalers per 30 days (13.4 g = 2 inhalers = 400 doses) | B |
| albuterol sulfate 90 mcg/actuation oral inhaler, 18 g (Ventolin HFA) | 2 inhalers per 30 days (36 g = 2 inhalers = 400 doses) | B |
| albuterol sulfate 90 mcg/actuation oral inhaler, 3.7 g (Ventolin HFA) | 2 inhalers per 30 days (7.4 g = 2 inhalers = 60 doses) | B |
| albuterol sulfate 90 mcg/actuation oral inhaler, 8 g (Ventolin HFA) | 2 inhalers per 30 days (16 g = 2 inhalers = 120 doses) | B |
| alendronate 10 mg tablets (Fosamax) | 30 tablets per 30 days | BG |
| alendronate 35 mg tablets (Fosamax) | 4 tablets per 28 days (1 pack = 4 tablets) | BG |
| alendronate 40 mg tablets (Fosamax) | 30 tablets per 30 days | B |
| alendronate 5 mg tablets (Fosamax) | 30 tablets per 30 days | BG |
| alendronate 70 mg effervescent tablets (Binosto) | 4 tablets per 28 days (1 pack = 4 tablets) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| alendronate 70 mg tablets (Fosamax) | 4 tablets per 28 days (1 pack = 4 tablets) | BG |
| alendronate 70 mg/75 mL oral solution (Alendronate Solution) | 300 mL per 28 days | B |
| alendronate/cholecalciferol 70-2800 mg-IU tablets (Fosamax Plus D) | 4 tablets per 28 days (IU = International Units, 1 pack = 4 tablets) | B |
| alendronate/cholecalciferol 70-5600 mg-IU tablets (Fosamax Plus D) | 4 tablets per 28 days (IU = International Units, 1 pack = 4 tablets) | B |
| alirocumab 150 mg/mL prefilled syringe (Praluent) | 2 pens per 28 days (1 package = 2mLs = 2 pens) | B |
| alirocumab 150 mg/mL subcutaneous pen-injector (Praluent) | 2 pens per 28 days (1 package = 2mLs = 2 pens) | B |
| alirocumab 75 mg/mL prefilled syringe (Praluent) | 2 pens per 28 days (1 package = 2mLs = 2 pens) | B |
| alirocumab 75 mg/mL subcutaneous pen-injector (Praluent) | 2 pens per 28 days (1 package = 2mLs = 2 pens) | B |
| almotriptan 12.5 mg tablets (Axert) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| almotriptan 6.25 mg tablets (Axert) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| alosetron 0.5 mg tablet (Lotronex) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| alosetron 1 mg tablet (Lotronex) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| Alphatrex 0.05% gel (betamethasone dipropionate augmented) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| alprostadil 10 mcg injection kit (Caverject) | 8 kits per 30 days | B |
| alprostadil 10 mcg injection kit (Edex) | 4 kits per 30 days | B |
| alprostadil 1000 mcg urethral pellet (Muse) | 8 kits per 30 days | B |
| alprostadil 125 mcg urethral pellet (Muse) | 8 kits per 30 days | B |
| alprostadil 20 mcg injection (Caverject) | 8 kits per 30 days | B |
| alprostadil 20 mcg injection kit (Caverject) | 8 kits per 30 days | B |
| alprostadil 20 mcg injection kit (Edex) | 4 kits per 30 days | B |
| alprostadil 250 mcg urethral pellet (Muse) | 8 kits per 30 days | B |
| alprostadil 40 mcg injection (Caverject) | 8 kits per 30 days | B |
| alprostadil 40 mcg injection kit (Edex) | 4 kits per 30 days | B |
| alprostadil 500 mcg urethral pellet (Muse) | 8 kits per 30 days | B |
| amantadine 129 mg tablet, extended-release (Osmolex) | 30 tablets per 30 days | B |
| amantadine 137 mg capsule, extended-release (Gocovri) | 60 capsules per 30 days | B |
| amantadine 193 mg tablet, extended-release (Osmolex) | 30 tablets per 30 days | B |
| amantadine 258 mg tablet, extended-release (Osmolex) | 30 tablets per 30 days | B |
| amantadine 68.5 mg capsule, extended-release (Gocovri) | 30 capsules per 30 days | B |
| ambrisentan 10 mg tablets (Letairis) | 30 tablets per 30 days | BG |
| ambrisentan 5 mg tablets (Letairis) | 30 tablets per 30 days | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| amcinonide 0.1% cream (Amcinonide) | 180 grams per 90 days (QL is cumulative across agents) | B |
| amcinonide 0.1% lotion (Amcinonide) | 180 grams per 90 days (QL is cumulative across agents) | B |
| amcinonide 0.1% ointment (Amcinonide) | 180 grams per 90 days (QL is cumulative across agents) | B |
| amifampridine 10 mg tablet (Firdapse) | 240 tablets per 30 days | B |
| amikacin 590 mg/8.4 mL suspension, inhalation (Arikayce) | 28 vials per 28 days | B |
| amphetamine 10 mg tablet (Evekeo) | 180 tablets per 30 days | BG |
| amphetamine 5 mg tablet (Evekeo) | 90 tablets per 30 days | BG |
| amphetamine extended-release 1.25 mg/mL suspension (Adzenys ER) | 450 mLs per 30 days | B |
| amphetamine extended-release 12.5 mg oral disintegrating tablet (Adzenys XR ODT) | 30 tablets per 30 days | B |
| amphetamine extended-release 15.7 mg oral disintegrating tablet (Adzenys XR ODT) | 30 tablets per 30 days | B |
| amphetamine extended-release 18.8 mg oral disintegrating tablet (Adzenys XR ODT) | 30 tablets per 30 days | B |
| amphetamine extended-release 2.5 mg/mL suspension (Dyanavel XR) | 240 mLs per 30 days | B |
| amphetamine extended-release 3.1 mg oral disintegrating tablet (Adzenys XR ODT) | 60 tablets per 30 days | B |
| amphetamine extended-release 6.3 mg oral disintegrating tablet (Adzenys XR ODT) | 60 tablets per 30 days | B |
| amphetamine extended-release 9.4 mg oral disintegrating tablet (Adzenys XR ODT) | 30 tablets per 30 days | B |
| amphetamine/dextroamphetamine 10 mg tablet (Adderall) | 60 tablets per 30 days | BG |
| amphetamine/dextroamphetamine 12.5 mg tablet (Adderall) | 60 tablets per 30 days | BG |
| amphetamine/dextroamphetamine 15 mg tablet (Adderall) | 60 tablets per 30 days | BG |
| amphetamine/dextroamphetamine 20 mg tablet (Adderall) | 90 tablets per 30 days | BG |
| amphetamine/dextroamphetamine 30 mg tablet (Adderall) | 60 tablets per 30 days | BG |
| amphetamine/dextroamphetamine 5 mg tablet (Adderall) | 60 tablets per 30 days | BG |
| amphetamine/dextroamphetamine 7.5 mg tablet (Adderall) | 60 tablets per 30 days | BG |
| amphetamine/dextroamphetamine extended-release 12.5 mg capsule (Mydayis) | 30 capsules per 30 days (QL is cumulative across agents) | B |
| amphetamine/dextroamphetamine extended-release 25 mg capsule (Mydayis) | 30 capsules per 30 days (QL is cumulative across agents) | B |
| amphetamine/dextroamphetamine extended-release 37.5 mg capsule (Mydayis) | 30 capsules per 30 days (QL is cumulative across agents) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| amphetamine/dextroamphetamine extended-release 50 mg capsule (Mydayis) | 30 capsules per 30 days (QL is cumulative across agents) | B |
| amphetamine/dextroamphetamine XR 10 mg capsule (Adderall XR) | 30 capsules per 30 days (QL is cumulative across agents) | BG |
| amphetamine/dextroamphetamine XR 15 mg capsule (Adderall XR) | 30 capsules per 30 days (QL is cumulative across agents) | BG |
| amphetamine/dextroamphetamine XR 20 mg capsule (Adderall XR) | 30 capsules per 30 days (QL is cumulative across agents) | BG |
| amphetamine/dextroamphetamine XR 25 mg capsule (Adderall XR) | 30 capsules per 30 days (QL is cumulative across agents) | BG |
| amphetamine/dextroamphetamine XR 30 mg capsule (Adderall XR) | 30 capsules per 30 days (QL is cumulative across agents) | BG |
| amphetamine/dextroamphetamine XR 5 mg capsule (Adderall XR) | 30 capsules per 30 days (QL is cumulative across agents) | BG |
| anakinra 100 mg syringe (Kineret) | 28 syringes per 28 days | B |
| apixaban 2.5 mg tablet (Eliquis) | 60 tablets per 30 days | B |
| apixaban 5 mg tablet (Eliquis) | 74 tablets per 30 days | B |
| apixaban 5 mg tablet, starter pack (Eliquis) | 1 pack per 180 days | B |
| apremilast 10,20,30 mg Starter kit (Otezla) | 1 kit per 180 days (27 tablets =1 kit) | B |
| apremilast 10,20,30 mg Starter kit (Otezla) | 1 kit per 180 days (55 tablets = 1 kit) | B |
| apremilast 30 mg tablets (Otezla) | 60 tablets per 30 days | B |
| aprepitant 1 x 125, 2 x 80 kit (Emend Therapy Pack) | 9 capsules per 30 days (9 caps = 3 therapy packs) | BG |
| aprepitant 125 mg capsule (Emend) | 3 capsules per 30 days | BG |
| aprepitant 125 mg capsule for oral suspension (Emend) | 9 kits per 30 days | B |
| aprepitant 40 mg capsule (Emend) | 2 capsules per 30 days | BG |
| aprepitant 80 mg capsule (Emend) | 6 capsules per 30 days | BG |
| aripiprazole 1 mg/mL oral solution (Abilify) | 900 mLs per 30 days | BG |
| aripiprazole 10 mg orally disintegrating tablet (Abilify Discmelt) | 60 tablets per 30 days | BG |
| aripiprazole 10 mg tablet (Abilify) | 30 tablets per 30 days | BG |
| aripiprazole 10 mg tablet with sensor (Abilify Mycite) | 30 tablets per 30 days | B |
| aripiprazole 15 mg orally disintegrating tablet (Abilify Discmelt) | 60 tablets per 30 days | BG |
| aripiprazole 15 mg tablet (Abilify) | 30 tablets per 30 days | BG |
| aripiprazole 15 mg tablet with sensor (Abilify Mycite) | 30 tablets per 30 days | B |
| aripiprazole 2 mg tablet (Abilify) | 60 tablets per 30 days | BG |
| aripiprazole 2 mg tablet with sensor (Abilify Mycite) | 30 tablets per 30 days | B |
| aripiprazole 20 mg tablet (Abilify) | 30 tablets per 30 days | BG |
| aripiprazole 20 mg tablet with sensor (Abilify Mycite) | 30 tablets per 30 days | B |
| aripiprazole 30 mg tablet (Abilify) | 30 tablets per 30 days | BG |
| aripiprazole 30 mg tablet with sensor (Abilify Mycite) | 30 tablets per 30 days | B |
| aripiprazole 5 mg tablet (Abilify) | 60 tablets per 30 days | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| aripiprazole 5 mg tablet with sensor (Abilify Mycite) | 30 tablets per 30 days | B |
| armodafinil 150 mg tablet (Nuvigil) | 30 tablets per 30 days | B |
| armodafinil 200 mg tablet (Nuvigil) | 30 tablets per 30 days | B |
| armodafinil 250 mg tablet (Nuvigil) | 30 tablets per 30 days | B |
| armodafinil 50 mg tablet (Nuvigil) | 30 tablets per 30 days | B |
| asenapine 10 mg sublingual tablet (Saphris) | 60 tablets per 30 days | B |
| asenapine 2.5 mg sublingual tablet (Saphris) | 60 tablets per 30 days | B |
| asenapine 5 mg sublingual tablet (Saphris) | 60 tablets per 30 days | B |
| aspirin/omeprazole 325-40 mg tablet (Yosprala) | 30 tablets per 30 days | B |
| aspirin/omeprazole 81-40 mg tablet (Yosprala) | 30 tablets per 30 days | B |
| atazanavir 150 mg capsule (Reyataz) | 30 capsules per 30 days | BG |
| atazanavir 200 mg capsule (Reyataz) | 60 capsules per 30 days | BG |
| atazanavir 300 mg capsule (Reyataz) | 30 capsules per 30 days | BG |
| atazanavir 50 mg powder for oral suspension (Reyataz) | 8 boxes per 30 days (30 packets = 1 box) | B |
| atazanavir-cobicistat 300-150 mg tablet (Evotaz) | 30 tablets per 30 days | B |
| atomoxetine 10 mg capsule (Strattera) | 60 capsules per 30 days | BG |
| atomoxetine 100 mg capsule (Strattera) | 30 capsules per 30 days | BG |
| atomoxetine 18 mg capsule (Strattera) | 60 capsules per 30 days | BG |
| atomoxetine 25 mg capsule (Strattera) | 60 capsules per 30 days | BG |
| atomoxetine 40 mg capsule (Strattera) | 60 capsules per 30 days | BG |
| atomoxetine 60 mg capsule (Strattera) | 30 capsules per 30 days | BG |
| atomoxetine 80 mg capsule (Strattera) | 30 capsules per 30 days | BG |
| atovaquone/proguanil 250 mg/100 mg tablet (Malarone) | 30 tablets per 90 days | BG |
| atovaquone/proguanil 62.5 mg/25 mg tablet (Malarone) | 30 tablets per 90 days | BG |
| avanafil 100 mg tablets (Stendra) | 8 tablets per 30 days (QL cumulative across agents) | B |
| avanafil 200 mg tablets (Stendra) | 8 tablets per 30 days (QL cumulative across agents) | B |
| avanafil 50 mg tablets (Stendra) | 8 tablets per 30 days (QL cumulative across agents) | B |
| avatrombopag 20 mg tablet (Doptelet) | 15 tablets per 5 days | B |
| azelastine 137 mcg/actuation nasal spray, 0.1% (Azelastine) | 60 mL per 30 days (60 mL = 2 bottles = 400 doses) | G |
| azelastine 205.5 mcg/actuation nasal spray, 0.15% (Astepro) | 60 mL per 30 days (60 mL = 2 bottles = 400 doses) | BG |
| azelastine/fluticasone 137-50 mcg/actuation nasal spray (Dymista) | 1 inhaler per 30 days (23 gm = 1 bottle = 120 doses) | B |
| azithromycin 250 mg tablets (Zithromax) | 60 tablets per 180 days (QL cumulative across strengths) | BG |
| azithromycin 500 mg tablets (Zithromax) | 60 tablets per 180 days (QL cumulative across strengths) | BG |
| azithromycin 600 mg tablets (Zithromax) | 60 tablets per 180 days (QL cumulative across strengths) | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| aztreonam 75 mg inhalation vials (Cayston) | 84 mL per 56 days (1 kit = 84 vials = 84 mL) | B |
| baloxavir marboxil 20 mg tablet, therapy pack (Xofluza) | 2 boxes per 120 days | B |
| baloxavir marboxil 40 mg tablet, therapy pack (Xofluza) | 2 boxes per 120 days | B |
| baracitinib 2 mg tablet (Olumiant) | 30 tablets per 30 days | B |
| becaplermin 0.01% gel (Regranex) | 60 grams per 365 days | B |
| beclomethasone 40 mcg/actuation oral inhaler (Qvar Redihaler) | 1 inhaler per 30 days (10.6 grams = 1 inhaler) | B |
| beclomethasone 40 mcg/actuation oral inhaler (Qvar) | 2 inhalers per 30 days (8.7 gm = 1 inhaler = 120 doses) | B |
| beclomethasone 42 mcg/actuation nasal spray (Beconase AQ) | 2 inhalers per 30 days (50 g = 2 bottles = 360 doses) | B |
| beclomethasone 80 mcg/actuation oral inhaler (Qvar Redihaler) | 2 inhalers per 30 days (21.2 grams = 2 inhalers) | B |
| beclomethasone 80 mcg/actuation oral inhaler (Qvar) | 2 inhalers per 30 days (8.7 gm, 120 actuations) | B |
| beclomethasone dipropionate 40 mcg/actuation nasal spray (Qnasl Child Spr) | 1 inhaler per 30 days (6.8 grams = 1 bottle = 60 doses) | B |
| beclomethasone dipropionate 80 mcg/actuation nasal spray (Qnasl) | 1 inhaler per 30 days (10.6 grams = 1 bottle = 120 doses) | B |
| belimumab 200 mg/mL autoinjector (Benlysta) | 4 autoinjectors per 28 days | B |
| belimumab 200 mg/mL prefilled syringe (Benlysta) | 4 syringes per 28 days | B |
| betamethasone dipropionate 0.05% cream (betamethasone dipropionate) | 180 grams per 90 days (QL is cumulative across agents) | G |
| betamethasone dipropionate 0.05% lotion (betamethasone dipropionate) | 180 grams per 90 days (QL is cumulative across agents) | G |
| betamethasone dipropionate 0.05% ointment (betamethasone dipropionate) | 180 grams per 90 days (QL is cumulative across agents) | G |
| betamethasone dipropionate 0.05% spray (Sernivo) | 180 grams per 90 days (QL is cumulative across agents) | B |
| betamethasone dipropionate augmented 0.05% cream (Diprolene AF) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| betamethasone dipropionate augmented 0.05% lotion (Diprolene) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| betamethasone dipropionate augmented 0.05% ointment (Diprolene) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| betrixaban 40 mg capsule (Bevyxxa) | 43 capsules per 42 days | B |
| betrixaban 80 mg capsule (Bevyxxa) | 43 capsules per 42 days | B |
| biktegravir-emtricitabine-tenofovir 50-200-25 mg tablet (Biktarvy) | 30 tablets per 30 days | B |
| bimatoprost 0.01% ophthalmic solution (Lumigan) | 2.5 mL per 20 days | B |
| bimatoprost 0.03% ophthalmic solution (Lumigan) | 2.5 mL per 20 days | G |
| bosentan 125 mg tablets (Tracleer) | 60 tablets per 30 days | B |
| bosentan 32 mg tablets for oral suspension (Tracleer) | 120 tablets per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|--|--|
| bosentan 62.5 mg tablets (Tracleer) | 60 tablets per 30 days | B |
| brexpiprazole 0.25 mg tablet (Rexulti) | 30 tablets per 30 days | B |
| brexpiprazole 0.5 mg tablet (Rexulti) | 30 tablets per 30 days | B |
| brexpiprazole 1 mg tablet (Rexulti) | 30 tablets per 30 days | B |
| brexpiprazole 2 mg tablet (Rexulti) | 30 tablets per 30 days | B |
| brexpiprazole 3 mg tablet (Rexulti) | 30 tablets per 30 days | B |
| brexpiprazole 4 mg tablet (Rexulti) | 30 tablets per 30 days | B |
| brodalumab 210 mg/1.5 mL subcutaneous injection (Siliq) | 2 syringes per 28 days (2 syringes) | B |
| budesonide 0.25 mg/2mL solution for nebulization (Pulmicort Respules) | 120 mL per 30 days (120 mL = 2 packages) | BG |
| budesonide 0.5 mg/2mL solution for nebulization (Pulmicort Respules) | 120 mL per 30 days (120 mL = 2 packages) | BG |
| budesonide 1 mg/2mL solution for nebulization (Pulmicort Respules) | 60 mL per 30 days (60 mL = 1 package) | BG |
| budesonide 180 mcg/actuation oral inhaler (Pulmicort Flexhaler) | 2 inhalers per 30 days ((225 mg, 120 actuations)) | B |
| budesonide 32 mcg/actuation nasal spray (Rhinocort Aqua) | 2 inhalers per 30 days (17.2 g = 2 bottles = 120 doses) | BG |
| budesonide 90 mcg/actuation oral inhaler (Pulmicort Flexhaler) | 1 inhaler per 30 days ((165 mg, 60 actuations)) | B |
| budesonide/formoterol 160-4.5 mcg/actuation oral inhaler (Symbicort) | 1 inhaler per 30 days (10.2 g = 1 inhaler = 120 doses) | B |
| budesonide/formoterol 80-4.5 mcg/actuation oral inhaler (Symbicort) | 1 inhaler per 30 days (10.2 gm = 1 inhaler = 120 doses) | B |
| buprenorphine 10 mcg/hour transdermal system (Butrans) | 4 systems per 28 days (QL cumulative across strengths) | B |
| buprenorphine 15 mcg/hour transdermal system (Butrans) | 4 systems per 28 days (QL cumulative across strengths) | B |
| buprenorphine 150 mcg buccal film (Belbuca) | 60 films per 30 days (QL cumulative across strengths) | B |
| buprenorphine 2 mg sublingual tablet (Subutex) | 15 tablets per 90 days | BG |
| buprenorphine 20 mcg/hour transdermal system (Butrans) | 4 systems per 28 days (QL cumulative across strengths) | B |
| buprenorphine 300 mcg buccal film (Belbuca) | 60 films per 30 days (QL cumulative across strengths) | B |
| buprenorphine 450 mcg buccal film (Belbuca) | 60 films per 30 days (QL cumulative across strengths) | B |
| buprenorphine 5 mcg/hour transdermal system (Butrans) | 4 systems per 28 days (QL cumulative across strengths) | B |
| buprenorphine 600 mcg buccal film (Belbuca) | 60 films per 30 days (QL cumulative across strengths) | B |
| buprenorphine 7.5 mcg/hour transdermal system (Butrans) | 4 systems per 28 days (QL cumulative across strengths) | B |
| buprenorphine 75 mcg buccal film (Belbuca) | 60 films per 30 days (QL cumulative across strengths) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| buprenorphine 750 mcg buccal film (Belbuca) | 60 films per 30 days (QL cumulative across strengths) | B |
| buprenorphine 8 mg sublingual tablet (Subutex) | 15 tablets per 90 days | BG |
| buprenorphine 900 mcg buccal film (Belbuca) | 60 films per 30 days (QL cumulative across strengths) | B |
| buprenorphine/naloxone 0.7 mg/0.18 mg sublingual tablet (Zubsolv) | 90 tablets per 30 days (QL cumulative across agents) | B |
| buprenorphine/naloxone 1.4 mg/0.36 mg sublingual tablet (Zubsolv) | 90 tablets per 30 days (QL cumulative across agents) | B |
| buprenorphine/naloxone 11.4 mg/2.9 mg sublingual tablet (Zubsolv) | 90 tablets per 30 days (QL cumulative across agents) | B |
| buprenorphine/naloxone 12 mg/3 mg sublingual film (Suboxone) | 90 films per 30 days (QL cumulative across agents) | BG |
| buprenorphine/naloxone 2 mg/0.5 mg sublingual film (Suboxone) | 90 films per 30 days (QL cumulative across agents) | BG |
| buprenorphine/naloxone 2 mg/0.5 mg sublingual tablet (Suboxone) | 90 tablets per 30 days (QL cumulative across agents) | B |
| buprenorphine/naloxone 2.1 mg/0.3mg buccal film (Bunavail) | 90 films per 30 days (QL cumulative across agents) | B |
| buprenorphine/naloxone 2.9 mg/0.71 mg sublingual tablet (Zubsolv) | 90 tablets per 30 days (QL cumulative across agents) | B |
| buprenorphine/naloxone 4 mg/1 mg sublingual film (Suboxone) | 90 films per 30 days (QL cumulative across agents) | BG |
| buprenorphine/naloxone 4.2 mg/0.7mg buccal film (Bunavail) | 90 films per 30 days (QL cumulative across agents) | B |
| buprenorphine/naloxone 5.7 mg/1.4 mg sublingual tablet (Zubsolv) | 90 tablets per 30 days (QL cumulative across agents) | B |
| buprenorphine/naloxone 6.3 mg/1mg buccal film (Bunavail) | 90 films per 30 days (QL cumulative across agents) | B |
| buprenorphine/naloxone 8 mg/2 mg sublingual film (Suboxone) | 90 films per 30 days (QL cumulative across agents) | BG |
| buprenorphine/naloxone 8 mg/2 mg sublingual tablet (Suboxone) | 90 tablets per 30 days (QL cumulative across agents) | BG |
| buprenorphine/naloxone 8.6 mg/2.1 mg sublingual tablet (Zubsolv) | 90 tablets per 30 days (QL cumulative across agents) | B |
| butorphanol 10 mg/mL nasal spray (butorphanol) | 5 mLs per 30 days (5 mLs = 2 bottles) | BG |
| c1 esterase inhibitor [human] 2000 units/vial (Haegarda) | 24 vials per 28 days | B |
| c1 esterase inhibitor [human] 3000 units/vial (Haegarda) | 16 vials per 28 days | B |
| c1 esterase inhibitor [human] 500 units/box vial (Berinert) | 10 vials per 30 days | B |
| c1 esterase inhibitor [recombinant] 2100 units/vial (Ruconest) | 8 vials per 30 days | B |
| calcifediol 30 mcg capsules (Rayaldee) | 60 capsules per 30 days | B |
| calcipotriene-betamethasone dipropionate 0.005-0.064% foam (Enstilar) | 180 grams per 90 days (QL is cumulative across agents) | B |
| calcipotriene-betamethasone dipropionate 0.005-0.064% ointment (Taclonex) | 180 grams per 90 days (QL is cumulative across agents) | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|--|--|
| calcipotriene-betamethasone dipropionate 0.005-0.064% suspension (Taclonex) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| canagliflozin 100 mg tablet (Invokana) | 30 tablets per 30 days | B |
| canagliflozin 300 mg tablet (Invokana) | 30 tablets per 30 days | B |
| canagliflozin/metformin 150 mg/1000 mg tablet (Invokamet) | 60 tablets per 30 days | B |
| canagliflozin/metformin 150 mg/500 mg tablet (Invokamet) | 60 tablets per 30 days | B |
| canagliflozin/metformin 50 mg/1000 mg tablet (Invokamet) | 60 tablets per 30 days | B |
| canagliflozin/metformin 50 mg/500 mg tablet (Invokamet) | 60 tablets per 30 days | B |
| canagliflozin/metformin extended-release 150 mg/1000 mg tablet (Invokamet XR) | 60 tablets per 30 days | B |
| canagliflozin/metformin extended-release 150 mg/500 mg tablet (Invokamet XR) | 60 tablets per 30 days | B |
| canagliflozin/metformin extended-release 50 mg/1000 mg tablet (Invokamet XR) | 60 tablets per 30 days | B |
| canagliflozin/metformin extended-release 50 mg/500 mg tablet (Invokamet XR) | 60 tablets per 30 days | B |
| cariprazine 1.5 & 3 mg therapy pack (Vraylar) | 1 pack per 180 days | B |
| cariprazine 1.5 mg capsule (Vraylar) | 30 capsules per 30 days | B |
| cariprazine 3 mg capsule (Vraylar) | 30 capsules per 30 days | B |
| cariprazine 4.5 mg capsule (Vraylar) | 30 capsules per 30 days | B |
| cariprazine 6 mg capsule (Vraylar) | 30 capsules per 30 days | B |
| celecoxib 100 mg capsules (Celebrex) | 60 capsules per 30 days | BG |
| celecoxib 200 mg capsules (Celebrex) | 60 capsules per 30 days | BG |
| celecoxib 400 mg capsules (Celebrex) | 30 capsules per 30 days | BG |
| celecoxib 50 mg capsules (Celebrex) | 60 capsules per 30 days | BG |
| cenegermin-bkbj 0.002% solution, ophthalmic (Oxervate) | 56 mL per 56 days | B |
| certolizumab 2 x 200 mg vial, kit (Cimzia) | 4 vials per 28 days | B |
| certolizumab 2 x 200 mg/mL syringe, kit (Cimzia) | 4 syringes per 28 days | B |
| certolizumab 6 x 200 mg/mL syringe, kit (Cimzia) | 1 kit per 180 days | B |
| cetrotirelix acetate 0.25 mg injection kit (Cetrotide) | 12 kits per 30 days | B |
| cetrotirelix acetate 3 mg injection kit (Cetrotide) | 1 kits per 30 days | B |
| choriogonadotropin 250 mcg/0.5 mL injection (Ovidrel) | 2 syringes per 30 days (2 syringes = 1 mL) | B |
| chorionic gonadotropin 10000 unit injection (Novarel) | 20 mL per 30 days | B |
| chorionic gonadotropin 5000 unit injection (Novarel) | 20 mL per 30 days | B |
| ciclesonide 160 mcg/actuation oral inhaler (Alvesco) | 2 inhalers per 30 days (12.2 g = 2 inhalers = 120 doses) | B |
| ciclesonide 37 mcg/actuation nasal spray (Zetonna) | 1 inhaler per 30 days (6.1 gm = 1 bottle = 60 doses) | B |
| ciclesonide 50 mcg/actuation nasal spray (Omnaris) | 1 inhaler per 30 days (12.5g = 1 bottle = 120 doses) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| ciclesonide 80 mcg/actuation oral inhaler (Alvesco) | 1 inhaler per 30 days (6.1 grams = 1 inhaler = 60 doses) | B |
| ciclopirox 8% solution (Penlac) | 6.6 mLs per 30 days | BG |
| cladribine 10 mg tablet, pack of 10 (Mavenclad) | 2 packs per 301 days | B |
| cladribine 10 mg tablet, pack of 4 (Mavenclad) | 2 packs per 301 days | B |
| cladribine 10 mg tablet, pack of 5 (Mavenclad) | 2 packs per 301 days | B |
| cladribine 10 mg tablet, pack of 6 (Mavenclad) | 2 packs per 301 days | B |
| cladribine 10 mg tablet, pack of 7 (Mavenclad) | 2 packs per 301 days | B |
| cladribine 10 mg tablet, pack of 8 (Mavenclad) | 1 pack per 301 days | B |
| cladribine 10 mg tablet, pack of 9 (Mavenclad) | 1 pack per 301 days | B |
| clarithromycin 500 mg extended-release tablets (Biaxin XL) | 28 tablets per 30 days | BG |
| clobetasol 0.05% aerosolized foam (Olux) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| clobetasol 0.05% aerosolized foam (Olux-E) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| clobetasol propionate 0.025% cream (Impoyz) | 180 grams per 90 days (QL is cumulative across agents) | B |
| clobetasol propionate 0.05% cream (Temovate) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| clobetasol propionate 0.05% lotion (Clobex) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| clobetasol propionate 0.05% ointment (Temovate) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| clobetasol propionate 0.05% solution (Temovate) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| clobetasol propionate 0.05% spray (Clobex) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| clonidine extended-release 0.1 mg ER tablet (Kapvay) | 120 tablets per 30 days (QL for 0.1 mg is 4/day until 2 mg strength avail.) | BG |
| clozapine 100 mg tablet (Clozaril) | 270 tablets per 30 days | BG |
| clozapine 100 mg tablet (FazaClo) | 90 tablets per 30 days | BG |
| clozapine 12.5 mg tablet (FazaClo) | 90 tablets per 30 days | BG |
| clozapine 150 mg tablet (FazaClo) | 180 tablets per 30 days | B |
| clozapine 200 mg tablet (Clozaril) | 120 tablets per 30 days | BG |
| clozapine 200 mg tablet (FazaClo) | 120 tablets per 30 days | B |
| clozapine 25 mg tablet (Clozaril) | 90 tablets per 30 days | BG |
| clozapine 25 mg tablet (FazaClo) | 270 tablets per 30 days | BG |
| clozapine 50 mg tablet (Clozaril) | 90 tablets per 30 days | BG |
| clozapine 50 mg/mL oral suspension (Versacloz) | 540 mL per 30 days | B |
| cobicistat 150 mg tablet (Tybost) | 30 tablets per 30 days | B |
| cromolyn sodium 20 mg/2 mL solution for nebulization (cromolyn sodium) | 240 mLs per Rx (240 mLs = 2 boxes) | G |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| cromolyn sodium 20 mg/2mL solution for nebulization (cromolyn sodium) | 240 mL per 30 days | B |
| cyanocobalamin 500 mcg/0.1 mL nasal spray (Nascobal) | 4 sprays per 28 days | B |
| cyclosporine 0.05% ophthalmic emulsion (Restasis Multidose) | 5.5 mLs per 30 days | B |
| cyclosporine 0.05% ophthalmic emulsion (Restasis) | 2 boxes per 30 days | B |
| cyclosporine 0.09% ophthalmic solution (Cequa) | 1 box per 30 days | B |
| dabigatran 110 mg capsule (Pradaxa) | 71 capsules per 180 days | B |
| dabigatran 150 mg capsule (Pradaxa) | 60 capsules per 30 days | B |
| dabigatran 75 mg capsule (Pradaxa) | 60 capsules per 30 days | B |
| dalfampridine 10 mg tablet (Ampyra) | 60 tablets per 30 days | BG |
| dalteparin 10000 IU/1 mL subcutaneous solution single-dose graduated syringe (Fragmin) | 360 units per 270 days (QL cumulative across agents) | B |
| dalteparin 12500 IU/0.5 mL subcutaneous solution single-dose syringe (Fragmin) | 360 units per 270 days (QL cumulative across agents) | B |
| dalteparin 15000 IU/0.6 mL subcutaneous solution single-dose syringe (Fragmin) | 360 units per 270 days (QL cumulative across agents) | B |
| dalteparin 18000 IU/0.72 mL subcutaneous solution single-dose syringe (Fragmin) | 360 units per 270 days (QL cumulative across agents) | B |
| dalteparin 2500 IU/0.2 mL subcutaneous solution single-dose syringe (Fragmin) | 360 units per 270 days (QL cumulative across agents) | B |
| dalteparin 25000 IU/1 mL subcutaneous solution single-dose syringe (Fragmin) | 95 units per 270 days | B |
| dalteparin 5000 IU/0.2 mL subcutaneous solution single-dose syringe (Fragmin) | 360 units per 270 days (QL cumulative across agents) | B |
| dalteparin 7500 IU/0.3 mL subcutaneous solution single-dose syringe (Fragmin) | 360 units per 270 days (QL cumulative across agents) | B |
| dalteparin 95000 IU/3.8 mL subcutaneous solution multi-dose vial (Fragmin) | 95 units per 270 days | B |
| dapagliflozin 10 mg tablet (Farxiga) | 30 tablets per 30 days | B |
| dapagliflozin 5 mg tablet (Farxiga) | 30 tablets per 30 days | B |
| dapagliflozin/metformin 10 mg/1000mg tablet (Xigduo XR) | 30 tablets per 30 days | B |
| dapagliflozin/metformin 10 mg/500mg tablet (Xigduo XR) | 30 tablets per 30 days | B |
| dapagliflozin/metformin 2.5 mg/1000mg tablet (Xigduo XR) | 60 tablets per 30 days | B |
| dapagliflozin/metformin 5 mg/1000mg tablet (Xigduo XR) | 60 tablets per 30 days | B |
| dapagliflozin/metformin 5 mg/500mg tablet (Xigduo XR) | 30 tablets per 30 days | B |
| dapagliflozin/saxagliptin 10-5 mg tablet (Qtern) | 30 tablets per 30 days | B |
| darunavir 100 mg/mL oral suspension (Prezista) | 400 mL per 30 days | B |
| darunavir 150 mg tablet (Prezista) | 180 tablets per 30 days | B |
| darunavir 600 mg tablet (Prezista) | 60 tablets per 30 days | B |
| darunavir 75 mg tablet (Prezista) | 300 tablets per 30 days | B |
| darunavir 800 mg tablet (Prezista) | 30 tablets per 30 days | B |
| darunavir-cobicistat 800-150 mg tablet (Prezcobix) | 30 tablets per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| darunavir-cobicistat-emtricitab-tenofovir 800-150-200-10 mg tablet (Symtuza) | 30 tablets per 30 days | B |
| deflazacort 18 mg tablet (Emflaza) | 30 tablets per 30 days | B |
| deflazacort 6 mg tablet (Emflaza) | 60 tablets per 30 days | B |
| delafloxacin meglumine 450 mg tablet (Baxdela) | 28 tablets per 180 days | B |
| delavirdine 100 mg tablet (Rescriptor) | 90 tablets per 30 days | B |
| delavirdine 200 mg tablet (Rescriptor) | 180 tablets per 30 days | B |
| desmopressin 0.83 mcg/0.1 mL nasal emulsion spray (Noctiva) | 1 bottle per 30 days | B |
| desmopressin 1.66 mcg/0.1 mL nasal emulsion spray (Noctiva) | 1 bottle per 30 days | B |
| desmopressin 27.7 mcg tablet, sublingual (Nocdurna) | 30 tablets per 30 days | B |
| desmopressin 55.3 mcg tablet, sublingual (Nocdurna) | 30 tablets per 30 days | B |
| desoximetasone 0.05% gel (Topicort) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| desoximetasone 0.05% ointment (Topicort) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| desoximetasone 0.25% cream (Topicort) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| desoximetasone 0.25% ointment (Topicort) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| desoximetasone 0.25% spray (Topicort) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| dexlansoprazole 30 mg delayed-release capsules (Dexilant) | 60 capsules per 30 days (QL cumulative across agents) | B |
| dexlansoprazole 60 mg delayed-release capsules (Dexilant) | 60 capsules per 30 days (QL cumulative across agents) | B |
| dexmethylphenidate 10 mg tablet (Focalin) | 60 tablets per 30 days | BG |
| dexmethylphenidate 2.5 mg tablet (Focalin) | 60 tablets per 30 days | BG |
| dexmethylphenidate 5 mg tablet (Focalin) | 60 tablets per 30 days | BG |
| dexmethylphenidate extended-release 10 mg capsule (Focalin XR) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| dexmethylphenidate extended-release 15 mg capsule (Focalin XR) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| dexmethylphenidate extended-release 20 mg capsule (Focalin XR) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| dexmethylphenidate extended-release 25 mg capsule (Focalin XR) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| dexmethylphenidate extended-release 30 mg capsule (Focalin XR) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| dexmethylphenidate extended-release 35 mg capsule (Focalin XR) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| dexmethylphenidate extended-release 40 mg capsule (Focalin XR) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|--|--|
| dexamethylphenidate extended-release 5 mg capsule (Focalin XR) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| dextroamphetamine 10 mg tablet (Dextroamphetamine) | 180 tablets per 30 days | BG |
| dextroamphetamine 15 mg tablet (Zenzedi) | 90 tablets per 30 days | B |
| dextroamphetamine 2.5 mg tablet (Zenzedi) | 90 tablets per 30 days | B |
| dextroamphetamine 20 mg tablet (Zenzedi) | 90 tablets per 30 days | B |
| dextroamphetamine 30 mg tablet (Zenzedi) | 60 tablets per 30 days | B |
| dextroamphetamine 5 mg tablet (Dextroamphetamine) | 90 tablets per 30 days | BG |
| dextroamphetamine 5 mg/5 mL solution (Procentra) | 1800 mL per 30 days | BG |
| dextroamphetamine 7.5 mg tablet (Zenzedi) | 90 tablets per 30 days | B |
| dextroamphetamine extended-release 10 mg ER capsule (Dexedrine) | 120 capsules per 30 days | BG |
| dextroamphetamine extended-release 15 mg ER capsule (Dexedrine) | 120 capsules per 30 days | BG |
| dextroamphetamine extended-release 5 mg ER capsule (Dexedrine) | 90 capsules per 30 days | BG |
| Diabetic supply (Glucose test disks) | 204 testing units per 30 days | B |
| Diabetic supply (Insulin Pen Needles) | 300 units per 30 days | B |
| Diabetic supply (Insulin Syringes) | 300 units per 30 days | B |
| dichlorphenamide 50 mg tablets (Keveyis) | 120 tablets per 30 days | B |
| diclofenac 3% gel (Solaraze) | 100 grams per Rx | BG |
| diclofenac 3% gel (Solaraze) | 300 grams per 180 days | BG |
| didanosine 10 mg/mL powder for solution, 100 mL bottle (Videx) | 1200 mL per 30 days | B |
| didanosine 10 mg/mL powder for solution, 200 mL bottle (Videx) | 1200 mL per 30 days | B |
| didanosine 125 mg capsule (Videx) | 30 capsules per 30 days | BG |
| didanosine 200 mg capsule (Videx) | 30 capsules per 30 days | BG |
| didanosine 250 mg capsule (Videx) | 30 capsules per 30 days | BG |
| didanosine 400 mg capsule (Videx) | 30 capsules per 30 days | BG |
| diflorasone 0.05% cream (Apexicon E) | 180 grams per 90 days (QL is cumulative across agents) | B |
| diflorasone 0.05% cream (Psorcon) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| diflorasone 0.05% ointment (Diflorasone) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| dihydroergotamine mesylate 1 mg/mL injection (D.H.E. 45) | 10 mL per 30 days | BG |
| dihydroergotamine mesylate 4 mg/mL nasal spray (Migranal) | 8 vials per 30 days (1 ampule = 1 mL) | B |
| dimethyl fumarate 120 mg capsule (Tecfidera) | 14 capsules per 180 days | B |
| dimethyl fumarate 240 mg capsules (Tecfidera) | 60 capsules per 30 days | B |
| dimethyl fumarate Starter kit (Tecfidera Starter Pack) | 60 capsules per 180 days | B |
| dolasetron 100 mg tablet (Anzemet) | 10 tablets per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| dolasetron 50 mg tablet (Anzemet) | 10 tablets per 30 days | B |
| dolutegravir 10 mg tablet (Tivicay) | 60 tablets per 30 days | B |
| dolutegravir 25 mg tablet (Tivicay) | 60 tablets per 30 days | B |
| dolutegravir 50 mg tablet (Tivicay) | 60 tablets per 30 days | B |
| dolutegravir-lamivudine 50-300 mg tablet (Dovato) | 30 tablets per 30 days | B |
| dolutegravir-rilpivirine 50-25 mg tablet (Juluca) | 30 tablets per 30 days | B |
| doravirine 100 mg tablet (Pifeltro) | 30 tablets per 30 days | B |
| doravirine-lamivudine-tenofovir 100-300-300 mg tablet (Delstrigo) | 30 tablets per 30 days | B |
| doxepin 3 mg tablet (Silenor) | 30 tablets per 30 days (QL cumulative across agents) | B |
| doxepin 6 mg tablet (Silenor) | 30 tablets per 30 days (QL cumulative across agents) | B |
| doxylamine-pyridoxine 10 mg/10 mg delayed release tablets (Diclegis) | 120 tablets per 30 days | B |
| doxylamine-pyridoxine 20 mg/20 mg extended-release tablet (Bonjesta) | 60 tablets per 30 days | B |
| dronabinol 10 mg capsules (Marinol) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| dronabinol 2.5 mg capsules (Marinol) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| dronabinol 5 mg capsules (Marinol) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| dronabinol 5 mg/mL oral solution (Syndros) | 4 bottles per 30 days | B |
| droxidopa 100 mg capsule (Northera) | 450 capsules per 30 days | B |
| droxidopa 200 mg capsule (Northera) | 180 capsules per 30 days | B |
| droxidopa 300 mg capsule (Northera) | 180 capsules per 30 days | B |
| dulaglutide 0.75 mg/0.5 mL syringes or pens (Trulicity) | 4 pens or syringes per 28 days | B |
| dulaglutide 1.5 mg/0.5 mL syringes or pens (Trulicity) | 4 pens or syringes per 28 days | B |
| dupilumab 200 mg/1.14 mL prefilled syringe (Dupixent) | 1 carton per 28 days 2 syringes = 2.28 mL | B |
| dupilumab 300 mg/2 mL prefilled syringe (Dupixent) | 1 carton per 28 days (1 carton = 2 syringes = 4 mLs) | B |
| edoxaban 15 mg tablet (Savaysa) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| edoxaban 30 mg tablet (Savaysa) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| edoxaban 60 mg tablet (Savaysa) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| efavirenz 200 mg capsule (Sustiva) | 60 tablets per 30 days | BG |
| efavirenz 50 mg capsule (Sustiva) | 90 tablets per 30 days | BG |
| efavirenz 600 mg tablet (Sustiva) | 30 tablets per 30 days | BG |
| efavirenz-emtricitabine-tenofovir 600-200-300 mg tablet (Atripla) | 30 tablets per 30 days | B |
| efavirenz-lamivudine-tenofovir 400-300-300 mg tablet (Symfi Lo) | 30 tablets per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| efavirenz-lamivudine-tenofovir 600-300-300 mg tablet (Symfi) | 30 tablets per 30 days | B |
| efinaconazole 10% solution (Jublia) | 4 mLs per 30 days | B |
| elagolix 150 mg tablet (Orilissa) | 30 tablets per 30 days | B |
| elagolix 200 mg tablet (Orilissa) | 60 tablets per 30 days | B |
| eletriptan 20 mg tablets (Relpax) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| eletriptan 40 mg tablets (Relpax) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| eliglustat 84 mg capsule (Cerdelga) | 60 capsules per 30 days | B |
| eltrombopag 12.5 mg powder packs for oral suspension (Promacta) | 30 packs per 30 days | B |
| eltrombopag 12.5 mg tablet (Promacta) | 30 tablets per 30 days | B |
| eltrombopag 25 mg tablet (Promacta) | 30 tablets per 30 days | B |
| eltrombopag 50 mg tablet (Promacta) | 60 tablets per 30 days | B |
| eltrombopag 75 mg tablet (Promacta) | 60 tablets per 30 days | B |
| eluxadoline 100 mg tablet (Viberzi) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| eluxadoline 75 mg tablet (Viberzi) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| elvitegravir 150 mg tablet (Vitekta) | 30 tablets per 30 days | B |
| elvitegravir 85 mg tablet (Vitekta) | 30 tablets per 30 days | B |
| elvitegravir-cobicistat-emtricitabine-tenofovir 150-150-200-10 mg tablet (Genvoya) | 30 tablets per 30 days | B |
| elvitegravir-cobicistat-emtricitabine-tenofovir 150-150-200-300 mg tablet (Stribild) | 30 tablets per 30 days | B |
| empagliflozin 10 mg tablet (Jardiance) | 30 tablets per 30 days | B |
| empagliflozin 25 mg tablet (Jardiance) | 30 tablets per 30 days | B |
| empagliflozin/linagliptin 10-5 mg tablet (Glyxambi) | 30 tablets per 30 days | B |
| empagliflozin/linagliptin 25-5 mg tablet (Glyxambi) | 30 tablets per 30 days | B |
| empagliflozin/metformin 12.5 mg/1000mg tablet (Synjardy) | 60 tablets per 30 days | B |
| empagliflozin/metformin 12.5 mg/500mg tablet (Synjardy) | 60 tablets per 30 days | B |
| empagliflozin/metformin 5 mg/1000mg tablet (Synjardy) | 60 tablets per 30 days | B |
| empagliflozin/metformin 5 mg/500mg tablet (Synjardy) | 60 tablets per 30 days | B |
| empagliflozin/metformin extended-release 10 mg/1000 mg tablet (Synjardy XR) | 60 tablets per 30 days | B |
| empagliflozin/metformin extended-release 12.5 mg/1000 mg tablet (Synjardy XR) | 60 tablets per 30 days | B |
| empagliflozin/metformin extended-release 25 mg/1000 mg tablet (Synjardy XR) | 30 tablets per 30 days | B |
| empagliflozin/metformin extended-release 5 mg/1000 mg tablet (Synjardy XR) | 60 tablets per 30 days | B |
| emtricitabine 10 mg/mL oral solution (Emtriva) | 720 mLs per 30 days | B |
| emtricitabine 200 mg capsule (Emtriva) | 30 capsules per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| emtricitabine- rilpivirine-tenofovir 200-25-25 mg tablet (Odefsey) | 30 tablets per 30 days | B |
| emtricitabine- rilpivirine-tenofovir 200-25-300 mg tablet (Complera) | 30 tablets per 30 days | B |
| emtricitabine-tenofovir alafenamide 200-25 mg tablet (Descovy) | 30 tablets per 30 days | B |
| emtricitabine-tenofovir disoproxil 100-150 mg tablet (Truvada) | 30 tablets per 30 days | B |
| emtricitabine-tenofovir disoproxil 133-200 mg tablet (Truvada) | 30 tablets per 30 days | B |
| emtricitabine-tenofovir disoproxil 167-250 mg tablet (Truvada) | 30 tablets per 30 days | B |
| emtricitabine-tenofovir disoproxil 200-300 mg tablet (Truvada) | 30 tablets per 30 days | B |
| enfuvirtide 90 mg/mL powder for solution (Fuzeon) | 60 vials per 30 days (108 mg/vial) | B |
| enfuvirtide 90 mg/mL powder for solution kit (Fuzeon) | 1 kit per 30 days (108 mg/vial) | B |
| enoxaparin 100 mg/1 mL subcutaneous solution single-dose graduated syringe (Lovenox) | 360 units per 270 days (QL cumulative across agents) | BG |
| enoxaparin 120 mg/0.8 mL subcutaneous solution single-dose graduated syringe (Lovenox) | 360 units per 270 days (QL cumulative across agents) | BG |
| enoxaparin 150 mg/1 mL subcutaneous solution single-dose graduated syringe (Lovenox) | 360 units per 270 days (QL cumulative across agents) | BG |
| enoxaparin 30 mg/0.3 mL subcutaneous solution single-dose syringe (Lovenox) | 360 units per 270 days (QL cumulative across agents) | BG |
| enoxaparin 300 mg/3 mL subcutaneous solution multiple-dose vial (Lovenox) | 360 units per 270 days (QL cumulative across agents) | BG |
| enoxaparin 40 mg/0.4 mL subcutaneous solution single-dose syringe (Lovenox) | 360 units per 270 days (QL cumulative across agents) | BG |
| enoxaparin 60 mg/0.6 mL subcutaneous solution single-dose graduated syringe (Lovenox) | 360 units per 270 days (QL cumulative across agents) | BG |
| enoxaparin 80 mg/0.8 mL subcutaneous solution single-dose graduated syringe (Lovenox) | 360 units per 270 days (QL cumulative across agents) | BG |
| ereumab-aooe 140 mg/mL auto-injector (Aimovig) | 1 injector per 30 days | B |
| ereumab-aooe 70 mg/mL autoinjector, single-dose (Aimovig) | 1 injector per 30 days | B |
| ereumab-aooe 70 x 2 mg/mL autoinjector, single-dose (Aimovig) | 1 box per 30 days 2 mL = 2 injectors | B |
| ertugliflozin/sitagliptin 15-100 mg tablet (Steglujan) | 30 tablets per 30 days | B |
| ertugliflozin/sitagliptin 5-100 mg tablet (Steglujan) | 30 tablets per 30 days | B |
| ertugliflozin-metformin 2.5 mg/1000 mg tablet (Segluromet) | 60 tablets per 30 days | B |
| ertugliflozin-metformin 2.5 mg/500 mg tablet (Segluromet) | 120 tablets per 30 days | B |
| ertugliflozin-metformin 7.5 mg/1000 mg tablet (Segluromet) | 60 tablets per 30 days | B |
| ertugliflozin-metformin 7.5 mg/500 mg tablet (Segluromet) | 60 tablets per 30 days | B |
| ertugliflozin-pyroglyutamic acid 15 mg tablet (Steglatro) | 30 tablets per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| ertugliflozin-pyroglyutamic acid 5 mg tablet (Steglatro) | 60 tablets per 30 days | B |
| esomeprazole 10 mg delayed-release oral suspension (Nexium) | 60 packets per 30 days (QL cumulative across agents) | B |
| esomeprazole 2.5 mg delayed-release oral suspension (Nexium) | 60 packets per 30 days (QL cumulative across agents) | B |
| esomeprazole 20 mg delayed-release capsules (Nexium) | 60 capsules per 30 days (QL cumulative across agents) | BG |
| esomeprazole 20 mg delayed-release oral suspension (Nexium) | 60 packets per 30 days (QL cumulative across agents) | B |
| esomeprazole 40 mg delayed-release capsules (Nexium) | 60 capsules per 30 days (QL cumulative across agents) | BG |
| esomeprazole 40 mg delayed-release oral suspension (Nexium) | 60 packets per 30 days (QL cumulative across agents) | B |
| esomeprazole 5 mg delayed-release oral suspension (Nexium) | 60 packets per 30 days (QL cumulative across agents) | B |
| esomeprazole strontium 24.65 mg delayed-release capsules (esomeprazole strontium) | 60 capsule per 30 days (QL cumulative across agents) | B |
| esomeprazole strontium 49.3 mg delayed-release capsules (esomeprazole strontium) | 60 capsule per 30 days (QL cumulative across agents) | B |
| estradiol 0.025 mg/24 hours patch (Alora) | 30 patches per 30 days | BG |
| estradiol 0.025 mg/24 hours patch (Climara) | 30 patches per 30 days | BG |
| estradiol 0.025 mg/24 hours patch (Minivelle) | 30 patches per 30 days | B |
| estradiol 0.025 mg/24 hours patch (Vivelle-Dot) | 30 patches per 30 days | BG |
| estradiol 0.0375 mg/24 hours patch (Climara) | 30 patches per 30 days | BG |
| estradiol 0.0375 mg/24 hours patch (Minivelle) | 30 patches per 30 days | B |
| estradiol 0.0375 mg/24 hours patch (Vivelle-Dot) | 30 patches per 30 days | BG |
| estradiol 0.05 mg/24 hours patch (Alora) | 30 patches per 30 days | BG |
| estradiol 0.05 mg/24 hours patch (Climara) | 30 patches per 30 days | BG |
| estradiol 0.05 mg/24 hours patch (Estraderm) | 30 patches per 30 days | B |
| estradiol 0.05 mg/24 hours patch (Minivelle) | 30 patches per 30 days | B |
| estradiol 0.05 mg/24 hours patch (Vivelle-Dot) | 30 patches per 30 days | BG |
| estradiol 0.06 mg/24 hours patch (Climara) | 30 patches per 30 days | BG |
| estradiol 0.075 mg/24 hours patch (Alora) | 30 patches per 30 days | BG |
| estradiol 0.075 mg/24 hours patch (Climara) | 30 patches per 30 days | BG |
| estradiol 0.075 mg/24 hours patch (Minivelle) | 30 patches per 30 days | B |
| estradiol 0.075 mg/24 hours patch (Vivelle-Dot) | 30 patches per 30 days | BG |
| estradiol 0.1 mg/24 hours patch (Alora) | 30 patches per 30 days | BG |
| estradiol 0.1 mg/24 hours patch (Climara) | 30 patches per 30 days | BG |
| estradiol 0.1 mg/24 hours patch (Estraderm) | 30 patches per 30 days | B |
| estradiol 0.1 mg/24 hours patch (Minivelle) | 30 patches per 30 days | B |
| estradiol 0.1 mg/24 hours patch (Vivelle-Dot) | 30 patches per 30 days | BG |
| estradiol 14 mcg/24 hours patch (Menostar) | 30 patches per 30 days | B |
| Estrogen contraceptives all strengths tablets (Estrogen contraceptives) | 28 tablets per 21 days | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| eszopiclone 1 mg tablet (Lunesta) | 30 tablets per 30 days (QL cumulative across agents) | BG |
| eszopiclone 2 mg tablet (Lunesta) | 30 tablets per 30 days (QL cumulative across agents) | BG |
| eszopiclone 3 mg tablet (Lunesta) | 30 tablets per 30 days (QL cumulative across agents) | BG |
| etanercept 25 mg/0.5 mL syringe (Enbrel) | 4 syringes per 28 days | B |
| etanercept 25 mg/vial, kit (Enbrel) | 8 vials per 28 days | B |
| etanercept 50 mg/mL autoinjector (Enbrel Sureclick) | 4 autoinjectors per 28 days (Psoriasis starting dose (8 syringes/ month for 3 months) may be approved through the PA process) | B |
| etanercept 50 mg/mL cartridge (Enbrel Mini) | 4 cartridges per 28 days (3.92 mLs = 4 cartridges) | B |
| etanercept 50 mg/mL syringe (Enbrel) | 4 syringes per 28 days (Psoriasis starting dose (8 syringes/ month for 3 months) may be approved through the PA process) | B |
| etonogestrel/ethinyl estradiol 0.120-0.015 mg/24 hours vaginal ring (Nuvaring) | 1 ring per 21 days | B |
| etravirine 100 mg tablet (Intelence) | 60 tablets per 30 days | B |
| etravirine 200 mg tablet (Intelence) | 60 tablets per 30 days | B |
| etravirine 25 mg tablet (Intelence) | 120 tablets per 30 days | B |
| evolocumab 140 mg/mL prefilled syringe (Repatha) | 2 syringes per 28 days | B |
| evolocumab 140 mg/mL subcutaneous auto-injector (Repatha SureClick) | 2 auto-injectors per 28 days | B |
| evolocumab 420 mg/3.5 mL single-use infusor with prefilled syringe (Repatha Pushtronex) | 1 infusor per 30 days | B |
| exenatide 10 mcg/dose prefilled pen (Byetta) | 2.4 mL per 30 days (2.4 mL = 1 pen = 60 doses) | B |
| exenatide 5 mcg/dose prefilled pen (Byetta) | 1.2 mL per 30 days (1.2 mL = 1 pen = 60 doses) | B |
| exenatide ER 2 mg/0.85 mL autoinjector (Bydureon BCise) | 4 pens per 28 days (3.4 mLs = 4 pens) | B |
| exenatide ER 2 mg/pen prefilled pen (Bydureon) | 4 pens per 28 days (4 pens = 1 carton) | B |
| exenatide ER 2 mg/vial powder for suspension dose tray (Bydureon) | 4 trays per 28 days (4 trays = 1 carton) | B |
| ezetimibe 10 mg tablets (Zetia) | 30 tablets per 30 days | BG |
| fenofibrate 120 mg tablets (Fenoglide) | 30 tablets per 30 days | BG |
| fenofibrate 130 mg micronized capsules (Antara) | 30 capsules per 30 days | BG |
| fenofibrate 134 mg micronized capsules (Lofibra) | 30 capsules per 30 days | BG |
| fenofibrate 145 mg tablets (Tricor) | 30 tablets per 30 days | BG |
| fenofibrate 150 mg capsules (Lipofen) | 30 capsules per 30 days | B |
| fenofibrate 160 mg tablets (Lofibra) | 30 tablets per 30 days | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|--|--|
| fenofibrate 160 mg tablets (Triglide) | 30 tablets per 30 days | B |
| fenofibrate 200 mg micronized capsules (Lofibra) | 30 capsules per 30 days | BG |
| fenofibrate 30 mg micronized capsules (Antara) | 60 capsules per 30 days | B |
| fenofibrate 40 mg tablets (Fenoglide) | 60 tablets per 30 days | BG |
| fenofibrate 43 mg micronized capsules (Antara) | 60 capsules per 30 days | BG |
| fenofibrate 48 mg tablets (Tricor) | 60 tablets per 30 days | BG |
| fenofibrate 50 mg capsules (Lipofen) | 60 capsules per 30 days | B |
| fenofibrate 50 mg tablets (Triglide) | 60 tablets per 30 days | B |
| fenofibrate 54 mg tablets (Lofibra) | 60 tablets per 30 days | BG |
| fenofibrate 67 mg micronized capsules (Lofibra) | 30 capsules per 30 days | BG |
| fenofibrate 90 mg micronized capsules (Antara) | 30 capsules per 30 days | B |
| fenofibric acid 105 mg tablets (Fibricor) | 30 tablets per 30 days | B |
| fenofibric acid 135 mg delayed-release tablets (Trilipix) | 30 tablets per 30 days | BG |
| fenofibric acid 35 mg tablets (Fibricor) | 60 tablets per 30 days | B |
| fenofibric acid 45 mg delayed-release tablets (Trilipix) | 60 tablets per 30 days | BG |
| fentanyl 100 mcg sublingual spray (Subsys) | 120 blister packs per 30 days (QL cumulative across agents) | B |
| fentanyl 100 mcg/hr transdermal patch (Duragesic) | 15 patches per 30 days (QL cumulative across strengths) | BG |
| fentanyl 100 mcg/spray nasal spray (Lazanda) | 30 bottles per 30 days | B |
| fentanyl 12 mcg/hr transdermal patch (Duragesic) | 15 patches per 30 days (QL cumulative across strengths) | BG |
| fentanyl 1200 mcg sublingual spray (Subsys) | 120 blister packs per 30 days (QL cumulative across agents) | B |
| fentanyl 1600 mcg sublingual spray (Subsys) | 120 blister packs per 30 days (QL cumulative across agents) | B |
| fentanyl 200 mcg sublingual spray (Subsys) | 120 blister packs per 30 days (QL cumulative across agents) | B |
| fentanyl 25 mcg/hr transdermal patch (Duragesic) | 15 patches per 30 days (QL cumulative across strengths) | BG |
| fentanyl 300 mcg/spray nasal spray (Lazanda) | 30 bottles per 30 days | B |
| fentanyl 37.5 mcg/hr transdermal patch (Fentanyl) | 15 patches per 30 days (QL cumulative across strengths) | BG |
| fentanyl 400 mcg sublingual spray (Subsys) | 120 blister packs per 30 days (QL cumulative across agents) | B |
| fentanyl 400 mcg/spray nasal spray (Lazanda) | 30 bottles per 30 days | B |
| fentanyl 50 mcg/hr transdermal patch (Duragesic) | 15 patches per 30 days (QL cumulative across strengths) | BG |
| fentanyl 600 mcg sublingual spray (Subsys) | 120 blister packs per 30 days (QL cumulative across agents) | B |
| fentanyl 62.5 mcg/hr transdermal patch (Fentanyl) | 15 patches per 30 days (QL cumulative across strengths) | BG |
| fentanyl 75 mcg/hr transdermal patch (Duragesic) | 15 patches per 30 days (QL cumulative across strengths) | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| fentanyl 800 mcg sublingual spray (Subsys) | 120 blister packs per 30 days (QL cumulative across agents) | B |
| fentanyl 87.5 mcg/hr transdermal patch (Fentanyl) | 15 patches per 30 days (QL cumulative across strengths) | BG |
| fentanyl citrate 100 mcg buccal tablet (Fentora) | 120 units per 30 days (QL cumulative across agents) | B |
| fentanyl citrate 100 mcg tablet (Abstral) | 120 units per 30 days (QL cumulative across agents) | B |
| fentanyl citrate 1200 mcg lozenge (Actiq) | 120 units per 30 days (QL cumulative across agents) | BG |
| fentanyl citrate 1600 mcg lozenge (Actiq) | 120 units per 30 days (QL cumulative across agents) | BG |
| fentanyl citrate 200 mcg buccal tablet (Fentora) | 120 units per 30 days (QL cumulative across agents) | B |
| fentanyl citrate 200 mcg lozenge (Actiq) | 120 units per 30 days (QL cumulative across agents) | BG |
| fentanyl citrate 200 mcg tablet (Abstral) | 120 units per 30 days (QL cumulative across agents) | B |
| fentanyl citrate 300 mcg tablet (Abstral) | 120 units per 30 days (QL cumulative across agents) | B |
| fentanyl citrate 400 mcg buccal tablet (Fentora) | 120 units per 30 days (QL cumulative across agents) | B |
| fentanyl citrate 400 mcg lozenge (Actiq) | 120 units per 30 days (QL cumulative across agents) | BG |
| fentanyl citrate 400 mcg tablet (Abstral) | 120 units per 30 days (QL cumulative across agents) | B |
| fentanyl citrate 600 mcg buccal tablet (Fentora) | 120 units per 30 days (QL cumulative across agents) | B |
| fentanyl citrate 600 mcg lozenge (Actiq) | 120 units per 30 days (QL cumulative across agents) | BG |
| fentanyl citrate 600 mcg tablet (Abstral) | 120 units per 30 days (QL cumulative across agents) | B |
| fentanyl citrate 800 mcg buccal tablet (Fentora) | 120 units per 30 days (QL cumulative across agents) | B |
| fentanyl citrate 800 mcg lozenge (Actiq) | 120 units per 30 days (QL cumulative across agents) | BG |
| fentanyl citrate 800 mcg tablet (Abstral) | 120 units per 30 days (QL cumulative across agents) | B |
| fingolimod 0.25 mg capsules (Gilenya) | 30 capsules per 30 days | B |
| fingolimod 0.5 mg capsules (Gilenya) | 30 capsules per 30 days | B |
| fluandrenolide 4 mcg/sqcm tape, 24x3 (Cordran tape) | 180 grams per 90 days (QL is cumulative across agents) | B |
| flunisolide 25 mcg/actuation nasal spray (Flunisolide) | 75 mL per 30 days (75 mL = 3 bottles = 600 doses) | BG |
| flunisolide 29 mcg/actuation nasal spray (Flunisolide) | 75 mL per 30 days (75 mL = 3 bottles = 600 doses) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| flunisolide HFA 80 mcg/actuation oral inhaler (Aerospan) | 2 inhalers per 30 days (17.8 grams = 2 inhalers = 240 doses) | B |
| fluocinonide 0.05% cream (Fluocinonide) | 180 grams per 90 days (QL is cumulative across agents) | G |
| fluocinonide 0.05% emulsified base cream (Fluocinonide) | 180 grams per 90 days (QL is cumulative across agents) | G |
| fluocinonide 0.05% gel (Fluocinonide) | 180 grams per 90 days (QL is cumulative across agents) | G |
| fluocinonide 0.05% ointment (Fluocinonide) | 180 grams per 90 days (QL is cumulative across agents) | G |
| fluocinonide 0.05% solution (Fluocinonide) | 180 grams per 90 days (QL is cumulative across agents) | G |
| fluocinonide 0.10% cream (Vanos) | 120 grams per 180 days | BG |
| fluocinonide 0.10% cream (Vanos) | 60 grams per Rx | BG |
| fluorouracil 0.5% cream (Carac) | 30 grams per 180 days | B |
| fluorouracil 0.5% cream (Carac) | 30 grams per Rx | B |
| fluorouracil 0.5% cream (Fluorouracil) | 30 grams per 180 days | B |
| fluorouracil 0.5% cream (Fluorouracil) | 30 grams per Rx | B |
| fluorouracil 1% cream (Fluoroplex) | 30 grams per Rx | B |
| fluorouracil 1% cream (Fluoroplex) | 60 grams per 180 days | B |
| fluorouracil 4% cream (Tolak) | 40 grams per 180 days | B |
| fluorouracil 4% cream (Tolak) | 40 grams per Rx | B |
| fluorouracil 5% cream (Efudex) | 240 grams per 180 days | BG |
| fluorouracil 5% cream (Efudex) | 80 grams per Rx | BG |
| fluticasone 100 mcg/actuation oral inhaler (Arnuity Ellipta) | 1 inhaler per 30 days (30 blisters = 1 inhaler) | B |
| fluticasone 100 mcg/actuation oral inhaler (Flovent Diskus) | 60 blisters per 30 days (60 blisters = 1 inhaler = 60 doses) | B |
| fluticasone 110 mcg/actuation oral inhaler (Flovent HFA) | 1 inhaler per 30 days (12 grams = 1 inhaler = 120 doses) | B |
| fluticasone 113 mcg/actuation oral inhaler (Armonair) | 1 inhaler per 30 days | B |
| fluticasone 200 mcg/actuation oral inhaler (Arnuity Ellipta) | 1 inhaler per 30 days (30 blisters = 1 inhaler) | B |
| fluticasone 220 mcg/actuation oral inhaler (Flovent HFA) | 2 inhalers per 30 days (24 grams = 2 inhalers = 240 doses) | B |
| fluticasone 232 mcg/actuation oral inhaler (Armonair) | 1 inhaler per 30 days | B |
| fluticasone 250 mcg/actuation oral inhaler (Flovent Diskus) | 240 blisters per 30 days (240 blisters = 4 inhalers = 240 doses) | B |
| fluticasone 44 mcg/actuation oral inhaler (Flovent HFA) | 1 inhaler per 30 days (10.6 grams = 1 inhaler = 120 doses) | B |
| fluticasone 50 mcg/actuation oral inhaler (Arnuity Ellipta) | 1 inhaler per 30 days (30 blisters = 1 inhaler) | B |
| fluticasone 50 mcg/actuation oral inhaler (Flovent Diskus) | 60 blisters per 30 days (60 blisters = 1 inhaler = 60 doses) | B |
| fluticasone 55 mcg/actuation oral inhaler (Armonair) | 1 inhaler per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| fluticasone furoate/umeclidinium/vilanterol 100-62.5-25 mcg/actuation oral inhaler (Trelegy Ellipta) | 1 inhaler per 30 days (60 blisters = 1 inhaler) | B |
| fluticasone furoate/vilanterol 100-25 mcg/actuation oral inhaler (Breo Ellipta) | 1 inhaler per 30 days (60 blisters = 1 inhaler = 30 doses) | B |
| fluticasone furoate/vilanterol 200-25 mcg/actuation oral inhaler (Breo Ellipta) | 1 inhaler per 30 days (60 blisters = 1 inhaler = 30 doses) | B |
| fluticasone propionate 50 mcg/actuation nasal spray (Flonase) | 1 inhaler per 30 days (16 gm = 1 bottle = 120 doses per bottle) | BG |
| fluticasone propionate 93 mcg/actuation nasal spray (Xhance) | 2 bottles per 30 days (32 mLs = 2 bottles = 240 doses) | B |
| fluticasone/salmeterol 115-21 mcg/actuation oral inhaler (Advair HFA) | 1 inhaler per 30 days (12 g = 1 inhaler = 120 doses) | B |
| fluticasone/salmeterol 230-21 mcg/actuation oral inhaler (Advair HFA) | 1 inhaler per 30 days (12 g = 1 inhaler = 120 doses) | B |
| fluticasone/salmeterol 45-21 mcg/actuation oral inhaler (Advair HFA) | 1 inhaler per 30 days (12 g = 1 inhaler = 120 doses) | B |
| fluticasone/salmeterol 100-50 mcg/actuation oral inhaler (Advair Diskus) | 1 inhaler per 30 days (60 blisters = 1 inhaler = 60 doses) | BG |
| fluticasone/salmeterol 113-14 mcg/actuation oral inhaler (AirDuo RespiClick) | 1 inhaler per 30 days | B |
| fluticasone/salmeterol 232-14 mcg/actuation oral inhaler (AirDuo RespiClick) | 1 inhaler per 30 days | B |
| fluticasone/salmeterol 250-50 mcg/actuation oral inhaler (Advair Diskus) | 1 inhaler per 30 days (60 blisters = 1 inhaler = 60 doses) | BG |
| fluticasone/salmeterol 500-50 mcg/actuation oral inhaler (Advair Diskus) | 1 inhaler per 30 days (60 blisters = 1 inhaler = 60 doses) | BG |
| fluticasone/salmeterol 55-14 mcg/actuation oral inhaler (AirDuo RespiClick) | 1 inhaler per 30 days | B |
| follitropin alfa 1050 units/vial injection (Gonal-F) | 5 vials per 30 days | B |
| follitropin alfa 1050 units/vial injection (Gonal-F) | 5 vials per Rx | B |
| follitropin alfa 300 units/cartridge subcutaneous solution pen (Gonal-F RFF Rediject) | 15 cartridges per 30 days | B |
| follitropin alfa 450 units/cartridge subcutaneous solution pen (Gonal-F RFF Rediject) | 10 cartridges per 30 days | B |
| follitropin alfa 450 units/vial injection (Gonal-F) | 10 vials per 30 days | B |
| follitropin alfa 75 units/vial powder for subcutaneous solution (Gonal-F RFF) | 60 vials per 30 days | B |
| follitropin alfa 900 units/cartridge subcutaneous solution pen (Gonal-F RFF Rediject) | 5 cartridges per 30 days | B |
| follitropin alfa 900 units/cartridge subcutaneous solution pen (Gonal-F RFF Rediject) | 5 cartridges per Rx | B |
| follitropin beta 150 units/vial injectable solution vials (Follistim AQ) | 30 vials per 30 days | B |
| follitropin beta 150 units/vial injectable solution vials (Follistim AQ) | 30 vials per Rx | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| follitropin beta 300 units/cartridge injectable solution cartridges (Follistim AQ) | 15 cartridges per 30 days | B |
| follitropin beta 300 units/cartridge injectable solution cartridges (Follistim AQ) | 15 cartridges per Rx | B |
| follitropin beta 600 units/cartridge injectable solution cartridges (Follistim AQ) | 8 cartridges per 30 days | B |
| follitropin beta 600 units/cartridge injectable solution cartridges (Follistim AQ) | 8 cartridges per Rx | B |
| follitropin beta 75 units/vial injectable solution vials (Follistim AQ) | 60 vials per 30 days | B |
| follitropin beta 75 units/vial injectable solution vials (Follistim AQ) | 60 vials per Rx | B |
| follitropin beta 900 units/cartridge injectable solution cartridges (Follistim AQ) | 5 cartridges per 30 days | B |
| follitropin beta 900 units/cartridge injectable solution cartridges (Follistim AQ) | 5 cartridges per Rx | B |
| fondaparinux 10 mg/0.8 mL subcutaneous solution single-dose syringe (Arixtra) | 360 units per 270 days (QL cumulative across agents) | BG |
| fondaparinux 2.5 mg/0.5 mL subcutaneous solution single-dose syringe (Arixtra) | 360 units per 270 days (QL cumulative across agents) | BG |
| fondaparinux 5 mg/0.4 mL subcutaneous solution single-dose syringe (Arixtra) | 360 units per 270 days (QL cumulative across agents) | BG |
| fondaparinux 7.5 mg/0.6 mL subcutaneous solution single-dose syringe (Arixtra) | 360 units per 270 days (QL cumulative across agents) | BG |
| formoterol 12 mcg/actuation oral inhaler (Foradil Aerolizer) | 60 capsules per 30 days (Inhaler pack comes in 12 or 60 cap pkg size) | B |
| fosamprenavir 50 mg/mL oral suspension (Lexiva) | 1800 mLs per 30 days (225 mL bottle) | B |
| fosamprenavir 700 mg tablet (Lexiva) | 120 tablets per 30 days | BG |
| fostamatinib 100 mg tablet (Tavalisse) | 60 tablets per 30 days | B |
| fostamatinib 150 mg tablet (Tavalisse) | 60 tablets per 30 days | B |
| fremanezumab-vfrm 225 mg/1.5 mL prefilled syringe (Ajovy) | 3 syringes per 90 days 4.5 mL = 3 syringes | B |
| frovatriptan 2.5 mg tablets (Frova) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| gabapentin 300 & 600 mg starter pack extended-release tablets (Gralise) | 1 pack per 180 days (9-300 mg tablets and 69-600 mg tablets per pack) | B |
| gabapentin 300 mg extended-release tablets (Gralise) | 30 tablets per 30 days | B |
| gabapentin 600 mg extended-release tablets (Gralise) | 90 tablets per 30 days | B |
| gabapentin enacarbil 300 mg extended-release tablets (Horizant) | 60 tablets per 30 days | B |
| gabapentin enacarbil 600 mg extended-release tablets (Horizant) | 60 tablets per 30 days | B |
| galcanezumab-gnlm 120 mg/mL autoinjector (Emgality) | 1 injector per 30 days | B |
| galcanezumab-gnlm 120 mg/mL prefilled syringe (Emgality) | 1 syringe per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|--|--|
| ganirelix acetate 0.5 mL/syringe injection (Ganirelix Acetate) | 12 syringes per 30 days | BG |
| gemfibrozil 600 mg tablets (Lopid) | 60 tablets per 30 days | BG |
| glatiramer 20 mg/mL syringe (Copaxone) | 30 syringes per 30 days (30 syringes = 1 box) | BG |
| glatiramer 20 mg/mL syringe (Glatopa) | 1 kit per 30 days (1 kit= 30 syringes) | G |
| glatiramer 40 mg/mL syringe (Copaxone) | 12 syringes per 28 days (12 mL = 12 syringes) | BG |
| glycopyrrolate 15.6 mcg/actuation oral inhaler (Seebri Neohaler) | 60 capsules per 30 days (60 capsules = 1 box) | B |
| glycopyrrolate 25 mcg/mL solution for nebulization, Starter Kit (Lonhala Magnair) | 60 vials per 180 days | B |
| glycopyrrolate 25 mcg/mL solution for nebulization, Starter Kit (Lonhala Magnair) | 60 vials per 30 days | B |
| glycopyrrolate/formoterol 9-4.8 mcg/actuation oral inhaler (Bevespi Aerosphere) | 1 inhaler per 30 days (10.7 g= 1 inhaler) | B |
| glyopyrronium tisyolate 2.4% pad (Qbrexza) | 30 pads per 30 days | B |
| golimumab 100 mg/1 mL autoinjector (Simponi) | 1 syringe per 28 days | B |
| golimumab 100 mg/1 mL subcutaneous injection (Simponi) | 1 syringe per 28 days | B |
| golimumab 50 mg/0.5 mL autoinjector (Simponi) | 1 syringe per 28 days | B |
| golimumab 50 mg/0.5 mL subcutaneous injection (Simponi) | 1 syringe per 28 days | B |
| granisetron 1 mg tablets (Granisetron) | 20 tablets per 30 days | G |
| granisetron 2 mg/10 mL oral solution (Granisol) | 90 mL per 30 days | B |
| granisetron 3.1 mg/24 hours patch (Sancuso) | 3 patches per 30 days | B |
| guanfacine extended-release 1 mg ER tablet (Intuniv) | 30 tablets per 30 days | BG |
| guanfacine extended-release 2 mg ER tablet (Intuniv) | 30 tablets per 30 days | BG |
| guanfacine extended-release 3 mg ER tablet (Intuniv) | 30 tablets per 30 days | BG |
| guanfacine extended-release 4 mg ER tablet (Intuniv) | 30 tablets per 30 days | BG |
| guselkumab 100 mg/1 mL pen-injector (Tremfya) | 1 pen per 56 days | B |
| guselkumab 100 mg/1 mL prefilled syringe (Tremfya) | 1 syringe per 56 days | B |
| halcinonide 0.1% cream (Halog) | 180 grams per 90 days (QL is cumulative across agents) | B |
| halcinonide 0.1% ointment (Halog) | 180 grams per 90 days (QL is cumulative across agents) | B |
| halobetasol 0.01% lotion (Bryhali) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| halobetasol 0.05% aerosolized foam (Lexette) | 180 grams per 90 days (QL is cumulative across agents) | B |
| halobetasol 0.05% cream (Ultravate) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| halobetasol 0.05% lotion (Ultravate) | 180 grams per 90 days (QL is cumulative across agents) | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| halobetasol 0.05% ointment (Ultravate) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| halobetasol-tazarotene 0.01 - 0.045% lotion (Duobrii) | 180 grams per 90 days (QL is cumulative across agents) | B |
| hydrocodone ER 10 mg extended-release (abuse-deterrent) capsule (Zohydro ER) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 100 mg extended-release tablet (Hysingla) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 120 mg extended-release tablet (Hysingla) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 15 mg extended-release (abuse-deterrent) capsule (Zohydro ER) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 20 mg extended-release (abuse-deterrent) capsule (Zohydro ER) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 20 mg extended-release tablet (Hysingla) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 30 mg extended-release (abuse-deterrent) capsule (Zohydro ER) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 30 mg extended-release tablet (Hysingla) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 40 mg extended-release (abuse-deterrent) capsule (Zohydro ER) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 40 mg extended-release tablet (Hysingla) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 50 mg extended-release (abuse-deterrent) capsule (Zohydro ER) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 60 mg extended-release tablet (Hysingla) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| hydrocodone ER 80 mg extended-release tablet (Hysingla) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| hydromorphone 12 mg extended-release tablet (Exalgo) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| hydromorphone 16 mg extended-release tablet (Exalgo) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| hydromorphone 32 mg extended release tablet (Exalgo) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| hydromorphone 8 mg extended-release tablet (Exalgo) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| ibandronate 150 mg tablets (Boniva) | 1 tablet per 30 days | BG |
| ibandronate 3 mg/3 mL injection (Boniva) | 3 mL per 90 days | BG |
| ibuprofen/famotidine 800-26.6 mg tablet (Duexis) | 90 tablets per 30 days | B |
| icatibant 30 mg/3 mL syringe (Firazyr) | 18 mLs per 30 days (18 mLs = 6 syringes) | B |
| iloperidone 1 mg tablet (Fanapt) | 60 tablets per 30 days | B |
| iloperidone 10 mg tablet (Fanapt) | 60 tablets per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| iloperidone 12 mg tablet (Fanapt) | 60 tablets per 30 days | B |
| iloperidone 2 mg tablet (Fanapt) | 60 tablets per 30 days | B |
| iloperidone 4 mg tablet (Fanapt) | 60 tablets per 30 days | B |
| iloperidone 6 mg tablet (Fanapt) | 60 tablets per 30 days | B |
| iloperidone 8 mg tablet (Fanapt) | 60 tablets per 30 days | B |
| iloperidone Titration Pack (Fanapt) | 1 pack per 180 days | B |
| iloprost 10 mcg/mL solution for inhalation (Ventavis) | 9 packages per 30 days (1 package = 30 ampules) | B |
| iloprost 20 mcg/mL solution for inhalation (Ventavis) | 9 packages per 30 days (1 package = 30 ampules) | B |
| imiquimod 2.5% cream (Zyclara) | 7.5 grams per Rx | B |
| imiquimod 2.5% cream pump (Zyclara) | 15 grams per 180 days | B |
| imiquimod 3.75% cream packets (Zyclara) | 28 packets per Rx | B |
| imiquimod 3.75% cream packets (Zyclara) | 56 packets per 180 days | B |
| imiquimod 3.75% cream pump (Imiquimod) | 15 grams per 180 days | B |
| imiquimod 3.75% cream pump (Imiquimod) | 7.5 grams per Rx | B |
| imiquimod 3.75% cream pump (Zyclara) | 15 grams per 180 days | B |
| imiquimod 3.75% cream pump (Zyclara) | 7.5 grams per Rx | B |
| imiquimod 5% cream (Aldara) | 12 packets per Rx | BG |
| imiquimod 5% cream (Aldara) | 48 packets per 180 days | BG |
| indacaterol 75 mcg/actuation oral inhaler (Arcapta Neohaler) | 30 capsules per 30 days (30 capsules = 1 box) | B |
| indacaterol/glycopyrrolate 27.5-15.6 mcg/actuation oral inhaler (Utibron Neohaler) | 60 capsules per 30 days (60 capsules = 1 box) | B |
| indinavir 100 mg capsule (Crixivan) | 90 capsules per 30 days | B |
| indinavir 200 mg capsule (Crixivan) | 270 capsules per 30 days | B |
| indinavir 400 mg capsule (Crixivan) | 180 capsules per 30 days | B |
| ingenol mebutate 0.015% gel (Picato) | 3 tubes per 180 days (3 tubes = 1 box) | B |
| ingenol mebutate 0.015% gel (Picato) | 3 tubes per Rx | B |
| ingenol mebutate 0.05% gel (Picato) | 2 tubes per 180 days (2 tubes = 1 box) | B |
| ingenol mebutate 0.05% gel (Picato) | 2 tubes per Rx | B |
| inotersen 284 mg/1.5 mL prefilled syringe (Tegsedi) | 6 mL per 28 days | B |
| insulin aspart 100 units/mL pen-injector (Fiasp FlexTouch) | 100 mL per 30 days | B |
| insulin aspart 100 units/mL subcutaneous injection (Novolog) | 100 mL per 30 days | B |
| insulin aspart 100 units/mL vial (Fiasp) | 100 mL per 30 days | B |
| insulin degludec 100 units/mL subcutaneous injection (Tresiba FlexTouch) | 100 mL per 30 days | B |
| insulin degludec 100 units/mL vial (Tresiba) | 100 mL per 30 days | B |
| insulin degludec 200 units/mL subcutaneous injection (Tresiba FlexTouch) | 100 mL per 30 days | B |
| insulin degludec-liraglutide 100 units/3.6 mg/mL pen-injector (Xultophy) | 1 box per 30 days (15 mLs = 5 pens = 1 box) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| insulin detemir 100 units/mL subcutaneous injection (Levemir) | 100 mL per 30 days | B |
| insulin glargine 100 units/mL pen-injector (Basaglar Kwikpen) | 100 mL per 30 days | B |
| insulin glargine 100 units/mL subcutaneous injection (Lantus) | 100 mL per 30 days | B |
| insulin glargine 300 units/mL subcutaneous injection (Toujeo) | 100 mL per 30 days (1.5 mL= 1 pen; 3 pens per box) | B |
| insulin glargine-lixisenatide 100 units/33 mcg/mL pen-injector (Soliqua) | 1 box per 30 days (15 mLs = 5 pens = 1 box) | B |
| insulin glulisine 100 units/mL subcutaneous injection (Apidra) | 100 mL per 30 days | B |
| insulin human 12 units/cartridge inhalation powder (Afrezza) | 10 packs per 30 days (1 pack = 90 x 12 unit cartridges) | B |
| insulin human 4 & 8 units/cartridge inhalation powder (Afrezza) | 10 packs per 30 days (1 pack = 90 x 4 unit cartridges, 90 x 8 unit cartridges) | B |
| insulin human 4 & 8 units/cartridge inhalation powder (Afrezza) | 17 packs per 30 days (1 pack = 30 x 4 unit cartridges, 60 x 8 unit cartridges) | B |
| insulin human 4 & 8 units/cartridge inhalation powder (Afrezza) | 21 packs per 30 days (1 pack = 60 x 4 unit cartridges, 30 x 8 unit cartridges) | B |
| insulin human 4 , 8, & 12 units/cartridge inhalation powder (Afrezza) | 7 packs per 30 days (1 pack=60 x 4 unit cartridges, 60 x 8 unit cartridges, 60x12 unit cartridges) | B |
| insulin human 4 units/cartridge inhalation powder (Afrezza) | 28 packs per 30 days (1 pack = 90 cartridges) | B |
| insulin human 8 & 12 units/cartridge inhalation powder (Afrezza) | 12 packs per 30 days (1 pack = 60 x 8 unit cartridges, 30 x 12 unit cartridges) | B |
| insulin human 8 & 12 units/cartridge inhalation powder (Afrezza) | 6 packs per 30 days 1 pack = 90x 8 unit cartridges, 90 x 12 unit cartridges) | B |
| insulin human 8 units/cartridge inhalation powder (Afrezza) | 14 packs per 30 days (1 pack = 90x8 unit cartridges) | B |
| insulin isophane (NPH) 100 units/mL subcutaneous injection (Humulin N, Novolin N, Relion N) | 100 mL per 30 days | B |
| insulin lispro 100 units/mL multiply dose vial (Admelog) | 100 mLs per 30 days | B |
| insulin lispro 100 units/mL prefilled pens (Admelog) | 100 mLs per 30 days | B |
| insulin lispro 100 units/mL subcutaneous injection (Humalog Jr KwikPen) | 100 mL per 30 days | B |
| insulin lispro 100 units/mL subcutaneous injection (Humalog) | 100 mL per 30 days | B |
| insulin lispro 200 units/mL subcutaneous injection (Humalog KwikPen) | 100 mL per 30 days (2 pens = 6mLs) | B |
| insulin mixed (70/30) 100 units/mL subcutaneous injection (Humulin Mix) | 100 mL per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| insulin mixed (70/30) 100 units/mL subcutaneous injection (Novolog Mix) | 100 mL per 30 days | B |
| insulin mixed (75/25 or 50/50) 100 units/mL subcutaneous injection (Humalog Mix) | 100 mL per 30 days | B |
| insulin regular 100 units/mL subcutaneous injection (Humulin R, Novolin R, Relion R) | 100 mL per 30 days | B |
| insulin regular 500 units/mL subcutaneous injection (Humulin R KwikPen) | 100 mL per 30 days | B |
| insulin regular 500 units/mL subcutaneous injection (Humulin R) | 100 mL per 30 days | B |
| interferon β -1a 22 mcg/0.5 mL subcutaneous solution, autoinjector (Rebif Rebidose) | 12 syringes per 28 days (1 carton = 12 syringes, QL cumulative across strengths) | B |
| interferon β -1a 22 mcg/0.5 mL subcutaneous solution, prefilled syringe (Rebif) | 12 syringes per 28 days (1 carton = 12 syringes, QL cumulative across strengths) | B |
| interferon β -1a 30 mcg vial (Avonex) | 4 vials per 28 days (4 vials = 1 kit) | B |
| interferon β -1a 30 mcg/0.5 mL pen, autoinjector (Avonex) | 4 pens per 28 days (1 kit = 4 vials, QL cumulative across strengths) | B |
| interferon β -1a 30 mcg/0.5 mL prefilled syringe (Avonex) | 4 syringes per 28 days (1 kit = 4 vials, QL cumulative across strengths) | B |
| interferon β -1a 44 mcg/0.5 mL subcutaneous solution, autoinjector (Rebif Rebidose) | 12 syringes per 28 days (1 carton = 12 syringes, QL cumulative across strengths) | B |
| interferon β -1a 44 mcg/0.5 mL subcutaneous solution, prefilled syringe (Rebif) | 12 syringes per 28 days (1 carton = 12 syringes, QL cumulative across strengths) | B |
| interferon β -1a titration pack (Rebif Rebidose Titration Pack) | 1 kit per 180 days ((6 x 8.8 mcg/0.2 mL + 6 x 22 mcg/0.5 mL)= Titration pack) | B |
| interferon β -1a titration pack (Rebif Titration Pack) | 1 kit per 180 days | B |
| interferon β -1b 0.3 mg kit (Betaseron) | 14 vials/syringes per 28 days | B |
| interferon β -1b 0.3 mg vial + syringe with diluent (Betaseron) | 14 vials/syringes per 28 days (14 vials/syringes = 1 box) | B |
| interferon β -1b 0.3 mg vial + syringe with diluent (Extavia) | 15 vials/syringes per 30 days (15 vials/syringes = 1 box) | B |
| ipratropium 17 mcg/actuation oral inhaler (Atrovent HFA) | 2 inhalers per 30 days (25.8 g = 2 inhalers = 200 doses) | B |
| ipratropium 21 mcg/actuation nasal spray, 0.03% (Atrovent) | 60 mL per 30 days (60 mL = 2 bottles = 690 doses) | BG |
| ipratropium 42 mcg/actuation nasal spray, 0.06% (Atrovent) | 45 mL per 30 days (45 mL = 3 bottles = 495 doses) | BG |
| ipratropium bromide 0.02% solution for nebulization (ipratropium bromide) | 375 mL per 30 days (no brand available) | G |
| ipratropium/albuterol 20-100 mcg/actuation oral inhaler (Combivent Respimat) | 2 inhalers per 30 days (8 grams = 2 inhalers = 240 doses) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| ipratropium/albuterol sulfate 0.5-3 mg/3 mL solution for nebulization (Duoneb) | 540 mL per 30 days | BG |
| itraconazole 10 mg/mL oral solution (Sporanox) | 1200 mLs per 30 days | BG |
| itraconazole 100 mg capsule (Sporanox) | 120 capsules per 30 days | BG |
| itraconazole 200 mg tablet (Onmel) | 30 tablets per 30 days | B |
| ivabridine 5 mg tablet (Corlanor) | 60 tablets per 30 days | B |
| ivabridine 7.5 mg tablet (Corlanor) | 60 tablets per 30 days | B |
| ixekizumab 80 mg/1 mL autoinjector (Taltz) | 1 syringe per 28 days | B |
| ixekizumab 80 mg/1 mL prefilled syringe (Taltz) | 1 syringe per 28 days | B |
| ketorolac 10 mg tablets (Toradol) | 20 tablets per 30 days | BG |
| ketorolac 15.75 mg/actuation nasal spray (Sprix) | 5 bottles per 30 days (5, 1.7 gram bottles per pack) | B |
| lamivudine 10 mg/mL oral solution (Epivir) | 960 mL per 30 days | BG |
| lamivudine 150 mg tablet (Epivir) | 30 tablets per 30 days | BG |
| lamivudine 300 mg tablet (Epivir) | 30 tablets per 30 days | BG |
| lamivudine-tenofovir 300-300 mg tablet (Cimduo) | 30 tablets per 30 days | B |
| lamivudine-zidovudine 150-300 mg tablet (Combivir) | 60 tablets per 30 days | BG |
| lanadelumab-flyo 300 mg/2 mL vial (Takhzyro) | 4 mL per 28 days | B |
| lansoprazole 15 mg delayed-release capsules (Prevacid) | 60 capsules per 30 days (QL cumulative across agents) | BG |
| lansoprazole 15 mg orally disintegrating tablets (Prevacid Solutab) | 60 tablets per 30 days (QL cumulative across agents) | BG |
| lansoprazole 30 mg delayed-release capsules (Prevacid) | 60 capsules per 30 days (QL cumulative across agents) | BG |
| lansoprazole 30 mg orally disintegrating tablets (Prevacid Solutab) | 60 tablets per 30 days (QL cumulative across agents) | BG |
| latanoprost 0.005% ophthalmic solution (Xalatan) | 2.5 mL per 20 days | BG |
| latanoprost 0.005% ophthalmic solution (Xelpros) | 2.5 mL per 20 days | B |
| latanoprostene bunod 0.024% ophthalmic solution (Vyzulta) | 5 mL per 20 days | B |
| lesinurad 200 mg tablet (Zurampic) | 30 tablets per 30 days | B |
| lesinurad-allopurinol 200 mg/200 mg tablet (Duzallo) | 30 tablets per 30 days | B |
| lesinurad-allopurinol 200 mg/300 mg tablet (Duzallo) | 30 tablets per 30 days | B |
| letermovir 240 mg tablet (Prevymis) | 100 tablets per 180 days | B |
| letermovir 480 mg tablet (Prevymis) | 100 tablets per 180 days | B |
| levalbuterol 0.31 mg/3 mL solution for nebulization (Xopenex) | 288 mL per 30 days (288 mL = 4 boxes = 96 vials) | BG |
| levalbuterol 0.66 mg/3 mL solution for nebulization (Xopenex) | 288 mL per 30 days (288 mL = 4 boxes = 96 vials) | BG |
| levalbuterol 1.25 mg/0.5 mL solution for nebulization (Xopenex Concentrate) | 90 vials per 30 days (90 units = 3 boxes) | BG |
| levalbuterol 1.25 mg/3 mL solution for nebulization (Xopenex) | 288 mL per 30 days (288 mL = 4 boxes = 96 vials) | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| levalbuterol 45 mcg/actuation oral inhaler (Xopenex HFA) | 2 inhalers per 30 days (30 g = 2 inhalers = 400 doses) | B |
| levonorgestrel 0.57 mg tablets (Plan B) | 4 tablets per 365 days (covered for females age 16 yrs and under with Rx) | BG |
| levonorgestrel 1.5 mg tablets (Plan B One-Step) | 2 tablets per 365 days (covered for females age 16 yrs and under with Rx) | BG |
| levonorgestrel/ethinyl estradiol/folic acid/levomefolate 0.1 mg-20 mcg and 1mg FA tablets (Falessa Kit) | 1 kit per 21 days | B |
| lidcaine-tetracaine 7 -7% cream (Pliaglis) | 100 grams per 30 days | B |
| lidcaine-tetracaine 70 -70 mg topical patch (Synera) | 4 patches per 28 days | B |
| lidocaine 1.8% pad (ZTlido) | 120 pads per 30 days (cumulative QL across agents) | B |
| lidocaine 2% gel (Lidocaine) | 120 grams per 30 days (cumulative QL across agents) | G |
| lidocaine 4% gel (Astero) | 120 grams per 30 days (cumulative QL across agents) | B |
| lidocaine 4% solution (Xylocaine) | 120 grams per 30 days (cumulative QL across agents) | BG |
| lidocaine 5% ointment (Lidocaine) | 120 grams per 30 days (cumulative QL across agents) | BG |
| lidocaine 5% patch (Lidoderm) | 120 patches per 30 days (cumulative QL across agents) | BG |
| lifitegrast 5% ophthalmic solution (Xiidra) | 2 boxes per 30 days | B |
| linaclotide 145 mcg capsule (Linzess) | 30 capsules per 30 days QL cumulative across agents | B |
| linaclotide 290 mcg capsule (Linzess) | 30 capsules per 30 days QL cumulative across agents | B |
| linaclotide 72 mcg capsule (Linzess) | 30 capsules per 30 days QL cumulative across agents | B |
| linagliptin 5 mg tablet (Tradjenta) | 30 tablets per 30 days | B |
| linagliptin/metformin 2.5-1000 mg extended-release tablet (Jentadueto XR) | 60 tablets per 30 days | B |
| linagliptin/metformin 2.5-1000 mg tablet (Jentadueto) | 60 tablets per 30 days | B |
| linagliptin/metformin 2.5-500 mg tablet (Jentadueto) | 60 tablets per 30 days | B |
| linagliptin/metformin 2.5-850 mg tablet (Jentadueto) | 60 tablets per 30 days | B |
| linagliptin/metformin 5-1000 mg extended-release tablet (Jentadueto XR) | 30 tablets per 30 days | B |
| linezolid 100 mg/5 mL oral suspension (Zyvox) | 600 mL per 180 days | BG |
| linezolid 600 mg tablets (Zyvox) | 56 tablets per 180 days | BG |
| liraglutide 18 mg/3 mL prefilled pen (Victoza) | 9 mL per 30 days (9 mL = 3 pens) | B |
| lisdexamfetamine 10 mg capsule (Vyvanse) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 10 mg tablet, chewable (Vyvanse) | 30 tablets per 30 days (QL cumulative across strengths) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|--|--|
| lisdexamfetamine 20 mg capsule (Vyvanse) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 20 mg tablet, chewable (Vyvanse) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 30 mg capsule (Vyvanse) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 30 mg tablet, chewable (Vyvanse) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 40 mg capsule (Vyvanse) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 40 mg tablet, chewable (Vyvanse) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 50 mg capsule (Vyvanse) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 50 mg tablet, chewable (Vyvanse) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 60 mg capsule (Vyvanse) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 60 mg tablet, chewable (Vyvanse) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| lisdexamfetamine 70 mg capsule (Vyvanse) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| lixisenatide 10 mcg/0.2 mL and 20 mcg/0.2 mL prefilled pen, starter kit (Adlyxin) | 1 box per 180 days (6 mLs = 1 box) | B |
| lixisenatide 20 mcg/0.2 mL prefilled pen (Adlyxin) | 2 pens per 28 days (6 mLs = 2 pens) | B |
| lofexidine 0.18 mg tablets (Lucemyra) | 456 tablets per 365 days 228 tablets per Rx, 2 courses of treatment per year | B |
| lomitapide 10 mg capsule (Juxtapid) | 30 capsules per 30 days | B |
| lomitapide 15 mg capsule (Juxtapid) | 90 capsules per 30 days | B |
| lomitapide 20 mg capsule (Juxtapid) | 30 capsules per 30 days | B |
| lomitapide 30 mg capsule (Juxtapid) | 30 capsules per 30 days | B |
| lomitapide 40 mg capsule (Juxtapid) | 30 capsules per 30 days | B |
| lomitapide 5 mg capsule (Juxtapid) | 30 capsules per 30 days | B |
| lomitapide 60 mg capsule (Juxtapid) | 30 capsules per 30 days | B |
| lopinavir-ritonavir 100-25 mg tablet (Kaletra) | 180 tablets per 30 days | B |
| lopinavir-ritonavir 200-50 mg tablet (Kaletra) | 120 tablets per 30 days | B |
| lopinavir-ritonavir 80 mg/20 mL oral solution (Kaletra) | 3 bottles per 30 days (160 mL bottle) | BG |
| lubiprostone 24 mcg capsule (Amitiza) | 60 capsules per 30 days | B |
| lubiprostone 8 mcg capsule (Amitiza) | 60 capsules per 30 days | B |
| lurasidone 120 mg tablets (Latuda) | 30 tablets per 30 days | B |
| lurasidone 20 mg tablets (Latuda) | 30 tablets per 30 days | B |
| lurasidone 40 mg tablets (Latuda) | 30 tablets per 30 days | B |
| lurasidone 60 mg tablets (Latuda) | 30 tablets per 30 days | B |
| lurasidone 80 mg tablets (Latuda) | 60 tablets per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| lusutrombopag 3 mg tablet (Mulpleta) | 7 tablets per 7 days | B |
| lutropin alfa 75 unit injection (Luveris) | 14 vials per 30 days | B |
| macitentan 10 mg tablets (Opsumit) | 30 tablets per 30 days | B |
| maraviroc 150 mg tablet (Selzentry) | 60 tablets per 30 days | B |
| maraviroc 20 mg/mL oral solution (Selzentry) | 8 bottles per 30 days | B |
| maraviroc 25 mg tablet (Selzentry) | 240 tablets per 30 days | B |
| maraviroc 300 mg tablet (Selzentry) | 120 tablets per 30 days | B |
| maraviroc 75 mg tablet (Selzentry) | 60 tablets per 30 days | B |
| menotropins 75 unit injection (Menopur) | 60 vials per 30 days | B |
| menotropins 75 unit injection (Repronex) | 60 vials per 30 days | B |
| metformin extended release 1000 mg tablet (Fortamet) | 60 tablets per 30 days | BG |
| metformin extended release 1000 mg tablet (Glumetza) | 60 tablets per 30 days | BG |
| metformin extended release 500 mg tablet (Fortamet) | 150 tablets per 30 days | BG |
| metformin extended release 500 mg tablet (Glumetza) | 120 tablets per 30 days | BG |
| methamphetamine 5 mg tablet (Desoxyn) | 150 tablets per 30 days | BG |
| methylphenidate 10 mg tablet (Ritalin) | 90 tablets per 30 days | BG |
| methylphenidate 10 mg tablet, chewable (Methylphenidate Chewable) | 180 tablets per 30 days | BG |
| methylphenidate 10 mg/5 mL solution (Methylin) | 900 mL per 30 days | BG |
| methylphenidate 2.5 mg tablet, chewable (Methylphenidate Chewable) | 90 tablets per 30 days | G |
| methylphenidate 20 mg tablet (Ritalin) | 90 tablets per 30 days | BG |
| methylphenidate 5 mg tablet (Ritalin) | 90 tablets per 30 days | G |
| methylphenidate 5 mg tablet, chewable (Methylphenidate Chewable) | 90 tablets per 30 days | G |
| methylphenidate 5 mg/5 mL solution (Methylin) | 450 mL per 30 days | BG |
| methylphenidate extended-release 10 mg capsule (Aptensio XR) | 30 capsules per 30 days | B |
| methylphenidate extended-release 10 mg capsule (Metadate CD) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| methylphenidate extended-release 10 mg capsule (Ritalin LA) | 30 capsules per 30 days | BG |
| methylphenidate extended-release 10 mg tablet (Methylphenidate extended-release) | 30 tablets per 30 days | BG |
| methylphenidate extended-release 15 mg capsule (Aptensio XR) | 30 capsules per 30 days | B |
| methylphenidate extended-release 17.3 mg tablet, oral disintegrating (Cotempla XR-ODT) | 60 tablets per 30 days | B |
| methylphenidate extended-release 18 mg tablet (Concerta) | 30 tablets per 30 days | BG |
| Methylphenidate extended-release 18 mg tablet (Methylphenidate extended-release) | 30 tablets per 30 days | BG |
| methylphenidate extended-release 20 mg capsule (Aptensio XR) | 30 capsules per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| methylphenidate extended-release 20 mg capsule (Metadate CD) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| methylphenidate extended-release 20 mg capsule (Ritalin LA) | 30 capsules per 30 days | BG |
| methylphenidate extended-release 20 mg tablet (Metadate ER) | 90 tablets per 30 days | G |
| methylphenidate extended-release 20 mg tablet (Methylphenidate extended-release) | 90 tablets per 30 days | G |
| methylphenidate extended-release 25 mg/5 mL suspension (Quillivant XR) | 360 mL per 30 days | B |
| methylphenidate extended-release 25.9 mg tablet, oral disintegrating (Cotempla XR-ODT) | 60 tablets per 30 days | B |
| methylphenidate extended-release 27 mg tablet (Concerta) | 30 tablets per 30 days | BG |
| Methylphenidate extended-release 27 mg tablet (Methylphenidate extended-release) | 30 tablets per 30 days | B |
| methylphenidate extended-release 30 mg capsule (Aptensio XR) | 30 capsules per 30 days | B |
| methylphenidate extended-release 30 mg capsule (Metadate CD) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| methylphenidate extended-release 30 mg capsule (Ritalin LA) | 60 capsules per 30 days | BG |
| methylphenidate extended-release 36 mg tablet (Concerta) | 60 tablets per 30 days | BG |
| Methylphenidate extended-release 36 mg tablet (Methylphenidate extended-release) | 60 tablets per 30 days | B |
| methylphenidate extended-release 40 mg capsule (Aptensio XR) | 30 capsules per 30 days | B |
| methylphenidate extended-release 40 mg capsule (Metadate CD) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| methylphenidate extended-release 40 mg capsule (Ritalin LA) | 30 capsules per 30 days | BG |
| methylphenidate extended-release 50 mg capsule (Aptensio XR) | 30 capsules per 30 days | B |
| methylphenidate extended-release 50 mg capsule (Metadate CD) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| methylphenidate extended-release 54 mg tablet (Concerta) | 30 tablets per 30 days | BG |
| Methylphenidate extended-release 54 mg tablet (Methylphenidate extended-release) | 30 tablets per 30 days | B |
| methylphenidate extended-release 60 mg capsule (Aptensio XR) | 30 capsules per 30 days | B |
| methylphenidate extended-release 60 mg capsule (Metadate CD) | 30 capsules per 30 days (QL is cumulative across strengths) | BG |
| methylphenidate extended-release 60 mg capsule (Ritalin LA) | 30 capsules per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|--|--|
| methylphenidate extended-release 72 mg tablet (Methylphenidate ER) | 30 tablets per 30 days | B |
| methylphenidate extended-release 72 mg tablet (Relexxii) | 30 tablets per 30 days | B |
| methylphenidate extended-release 8.6 mg tablet, oral disintegrating (Cotempla XR-ODT) | 30 tablets per 30 days | B |
| methylphenidate transdermal patch 10 mg/9 hr patch (Daytrana) | 30 patches per 30 days | B |
| methylphenidate transdermal patch 15 mg/9 hr patch (Daytrana) | 30 patches per 30 days | B |
| methylphenidate transdermal patch 20 mg/9 hr patch (Daytrana) | 30 patches per 30 days | B |
| methylphenidate transdermal patch 30 mg/9 hr patch (Daytrana) | 30 patches per 30 days | B |
| methylphenidate extended-release 20 mg tablet, chewable (Quillichew ER) | 30 tablets per 30 days | B |
| methylphenidate extended-release 30 mg tablet, chewable (Quillichew ER) | 60 tablets per 30 days | B |
| methylphenidate extended-release 40 mg tablet, chewable (Quillichew ER) | 30 tablets per 30 days | B |
| mifepristone 300 mg tablet (Korlym) | 120 tablets per 30 days | B |
| migalastat 123 mg capsule (Galafold) | 14 capsules per 28 days | B |
| milnacipran 100 mg tablets (Savella) | 60 tablets per 30 days | B |
| milnacipran 12.5 mg tablets (Savella) | 60 tablets per 30 days | B |
| milnacipran 25 mg tablets (Savella) | 60 tablets per 30 days | B |
| milnacipran 50 mg tablets (Savella) | 60 tablets per 30 days | B |
| milnacipran titration pack (Savella) | 55 tablets per 180 days (55 tablets = 1 kit) | B |
| mipomersen 200 mg/mL subcutaneous injection (Kynamro) | 4 mLs per 30 days (4 mL = 4 injections) | B |
| modafinil 100 mg tablet (Provigil) | 30 tablets per 30 days | BG |
| modafinil 200 mg tablet (Provigil) | 30 tablets per 30 days | BG |
| mometasone 100 mcg/actuation oral inhaler (Asmanex HFA) | 1 inhaler per 30 days (13 gm = 1 inhaler = 120 doses) | B |
| mometasone 110 mcg/actuation oral inhaler (Asmanex) | 1 inhaler per 30 days ((135 mg, 30 actuations)) | B |
| mometasone 200 mcg/actuation oral inhaler (Asmanex HFA) | 1 inhaler per 30 days (13 gm = 1 inhaler = 120 doses) | B |
| mometasone 220 mcg/actuation oral inhaler (Asmanex) | 1 inhaler per 30 days ((240 mg, 30, 60, 120 actuations)) | B |
| mometasone 50 mcg/actuation nasal spray (Nasonex) | 1 inhaler per 30 days (17 g = 1 bottle = 120 doses) | BG |
| mometasone furoate 0.1% ointment (Elocon) | 180 grams per 90 days (QL is cumulative across agents) | BG |
| mometasone/formoterol 100-5 mcg/actuation oral inhaler (Dulera) | 1 inhaler per 30 days (13 gm = 1 inhaler = 120 doses) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| mometasone/formoterol 200-5 mcg/actuation oral inhaler (Dulera) | 1 inhaler per 30 days (13 g = 1 inhaler = 120 doses) | B |
| morphine- naltrexone 100-4 mg controlled release capsule (Embeda) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| morphine- naltrexone 20-0.8 mg controlled release capsule (Embeda) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| morphine- naltrexone 30-1.2 mg controlled release capsule (Embeda) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| morphine- naltrexone 50-2 mg controlled release capsule (Embeda) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| morphine- naltrexone 60-2.4 mg controlled release capsule (Embeda) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| morphine- naltrexone 80-3.2 mg controlled release capsule (Embeda) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 10 mg sustained-release capsule (Kadian) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 100 mg extended release (abuse-deterrent) tablet (Morphabond ER) | 60 tablets per 30 days | B |
| morphine sulfate 100 mg sustained-release capsule (Kadian) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 100 mg sustained-release tablet (MS Contin) | 90 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 120 mg sustained-release capsule (Avinza) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 120 mg sustained-release capsule (Morphine Sulfate) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 15 mg extended release (abuse-deterrent) tablet (Arymo ER) | 90 tablets per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 15 mg extended release (abuse-deterrent) tablet (Morphabond ER) | 60 tablets per 30 days | B |
| morphine sulfate 15 mg sustained-release tablet (MS Contin) | 90 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 20 mg sustained-release capsule (Kadian) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 200 mg sustained-release capsule (Kadian) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 200 mg sustained-release tablet (MS Contin) | 90 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 30 mg extended release (abuse-deterrent) tablet (Arymo ER) | 90 tablets per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 30 mg extended release (abuse-deterrent) tablet (Morphabond ER) | 60 tablets per 30 days | B |
| morphine sulfate 30 mg sustained-release capsule (Avinza) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 30 mg sustained-release capsule (Kadian) | 60 tablets per 30 days (QL cumulative across strengths) | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| morphine sulfate 30 mg sustained-release capsule (Morphine Sulfate) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 30 mg sustained-release tablet (MS Contin) | 90 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 40 mg sustained-release capsule (Kadian) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 45 mg sustained-release capsule (Avinza) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 45 mg sustained-release capsule (Morphine Sulfate) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 50 mg sustained-release capsule (Kadian) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 60 mg extended release (abuse-deterrent) tablet (Arymo ER) | 90 tablets per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 60 mg extended release (abuse-deterrent) tablet (Morphabond ER) | 60 tablets per 30 days | B |
| morphine sulfate 60 mg sustained-release capsule (Avinza) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 60 mg sustained-release capsule (Kadian) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 60 mg sustained-release capsule (Morphine Sulfate) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 60 mg sustained-release tablet (MS Contin) | 90 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 75 mg sustained-release capsule (Avinza) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 75 mg sustained-release capsule (Morphine Sulfate) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 80 mg sustained-release capsule (Kadian) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| morphine sulfate 90 mg sustained-release capsule (Avinza) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| morphine sulfate 90 mg sustained-release capsule (Morphine Sulfate) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| mupirocin 2% cream (Bactroban) | 120 grams per 90 days | BG |
| mupirocin 2% ointment, 1 g tube (Bactroban Nasal) | 10 grams per 30 days | B |
| naloxone 0.4 mg/0.4 mL autoinjector (Evzio) | 1 carton per 90 days (1 carton= 2 injectors) | B |
| naloxone 2 mg/0.4 mL autoinjector (Evzio) | 1 carton per 90 days (1 carton= 2 injectors) | B |
| naproxen 125 mg/5 mL suspension (Naprosyn) | 1800 mL per 30 days | B |
| naproxen/esomeprazole 375-20 mg tablet (Vimovo) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| naproxen/esomeprazole 500-20 mg tablet (Vimovo) | 60 tablets per 30 days (QL cumulative across strengths) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| naratriptan 1 mg tablets (Amerge) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| naratriptan 2.5 mg tablets (Amerge) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| nelfinavir 250 mg tablet (Viracept) | 270 tablets per 30 days | B |
| nelfinavir 625 mg tablet (Viracept) | 120 tablets per 30 days | B |
| netarsudil 0.02% ophthalmic solution (Rhopressa) | 2.5 mL per 20 days | B |
| netarsudil/latanoprost 0.02-0.005% ophthalmic solution (Rocklatan) | 2.5 mL per 20 days | B |
| netupitant-palonosetron 300 mg/0.5 mg capsule (Akynzeo) | 3 capsules per 30 days | B |
| nevirapine 100 mg extended-release tablet (Viramune XR) | 90 tablets per 30 days | BG |
| nevirapine 200 mg tablet (Viramune) | 60 tablets per 30 days | BG |
| nevirapine 400 mg extended-release tablet (Viramune XR) | 30 tablets per 30 days | BG |
| nevirapine 50 mg/5 mL oral suspension (Viramune) | 1200 mL per 30 days | BG |
| nintedanib 100 mg capsule (Ofev) | 60 capsules per 30 days | B |
| nintedanib 150 mg capsule (Ofev) | 60 capsules per 30 days | B |
| nitazoxanide 100 mg/5 mL oral solution (Alinia) | 150 mL per 30 days | B |
| nitazoxanide 500 mg tablet (Alinia) | 6 tablets per 30 days | B |
| norelgestromin/ethinyl estradiol all strengths patch (Ortho Evra/Xulane) | 4 patches per 21 days | B |
| obeticholic acid 10 mg tablet (Ocaliva) | 30 tablets per 30 days | B |
| obeticholic acid 5 mg tablet (Ocaliva) | 30 tablets per 30 days | B |
| olanzapine 10 mg orally disintegrating tablets (Zyprexa Zydis) | 30 tablets per 30 days | BG |
| olanzapine 10 mg tablet (Zyprexa) | 60 tablets per 30 days | BG |
| olanzapine 15 mg orally disintegrating tablets (Zyprexa Zydis) | 30 tablets per 30 days | BG |
| olanzapine 15 mg tablet (Zyprexa) | 30 tablets per 30 days | BG |
| olanzapine 2.5 mg tablet (Zyprexa) | 60 tablets per 30 days | BG |
| olanzapine 20 mg orally disintegrating tablets (Zyprexa Zydis) | 30 tablets per 30 days | BG |
| olanzapine 20 mg tablet (Zyprexa) | 30 tablets per 30 days | BG |
| olanzapine 5 mg orally disintegrating tablets (Zyprexa Zydis) | 30 tablets per 30 days | BG |
| olanzapine 5 mg tablet (Zyprexa) | 60 tablets per 30 days | BG |
| olanzapine 7.5 mg tablet (Zyprexa) | 60 tablets per 30 days | BG |
| olodaterol 2.5 mcg/actuation oral inhaler (Striverdi Respimat) | 1 inhaler per 30 days (4g = 1 inhaler = 60 actuations) | B |
| olopatadine 0.6% nasal spray (Patanase) | 1 inhaler per 30 days (30.5 g = 1 bottle = 240 doses) | BG |
| omadacycline 150 mg tablet (Nuzrya) | 30 tablets per 180 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| omeprazole 10 mg delayed-release capsules (Prilosec) | 60 capsules per 30 days (QL cumulative across agents) | BG |
| omeprazole 10 mg oral suspension packets (Prilosec) | 60 packets per 30 days (QL cumulative across agents) | B |
| omeprazole 2.5 mg oral suspension packets (Prilosec) | 60 packets per 30 days (QL cumulative across agents) | B |
| omeprazole 20 mg delayed-release capsules (Prilosec) | 60 capsules per 30 days (QL cumulative across agents) | BG |
| omeprazole 40 mg delayed-release capsules (Prilosec) | 60 capsules per 30 days (QL cumulative across agents) | BG |
| omeprazole/sodium bicarbonate 20 mg immediate-release capsules (Zegerid) | 60 capsules per 30 days (QL cumulative across agents) | BG |
| omeprazole/sodium bicarbonate 20 mg powder for oral suspension packets (Zegerid) | 60 packets per 30 days (QL cumulative across agents) | BG |
| omeprazole/sodium bicarbonate 40 mg immediate-release capsules (Zegerid) | 60 capsules per 30 days (QL cumulative across agents) | BG |
| omeprazole/sodium bicarbonate 40 mg powder for oral suspension packets (Zegerid) | 60 packets per 30 days (QL cumulative across agents) | BG |
| ondansetron 24 mg tablet (Zofran) | 1 tablet per 30 days | BG |
| ondansetron 4 mg orally disintegrating tablets (Zofran ODT) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| ondansetron 4 mg soluble film (Zuplenz) | 30 films per 30 days (QL cumulative across strengths) | B |
| ondansetron 4 mg tablet (Zofran) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| ondansetron 4 mg/5 mL oral solution (Zofran) | 300 mL per 30 days | BG |
| ondansetron 8 mg orally disintegrating tablets (Zofran ODT) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| ondansetron 8 mg soluble film (Zuplenz) | 30 films per 30 days (QL cumulative across strengths) | B |
| ondansetron 8 mg tablet (Zofran) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| oseltamivir 30 mg capsules (Tamiflu) | 40 capsules per 120 days | BG |
| oseltamivir 45 mg capsules (Tamiflu) | 20 capsules per 120 days (QL cumulative across strengths) | BG |
| oseltamivir 6 mg/mL oral suspension (Tamiflu) | 360 mLs per 120 days | BG |
| oseltamivir 75 mg capsules (Tamiflu) | 20 capsules per 120 days (QL cumulative across strengths) | BG |
| oxycodone ER 10 mg tablet (Oxycontin) | 120 tablets per 30 days (QL cumulative across strengths) | B |
| oxycodone ER 13.5 mg extended-release, abuse-deterrent capsule (Xtampza) | 240 capsules per 30 days (QL cumulative across strengths) | B |
| oxycodone ER 15 mg tablet (Oxycontin) | 120 tablets per 30 days (QL cumulative across strengths) | B |
| oxycodone ER 18 mg extended-release, abuse-deterrent capsule (Xtampza) | 240 capsules per 30 days (QL cumulative across strengths) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| oxycodone ER 20 mg tablet (Oxycontin) | 120 tablets per 30 days (QL cumulative across strengths) | B |
| oxycodone ER 27 mg extended-release, abuse-deterrent capsule (Xtampza) | 240 capsules per 30 days (QL cumulative across strengths) | B |
| oxycodone ER 30 mg tablet (Oxycontin) | 120 tablets per 30 days (QL cumulative across strengths) | B |
| oxycodone ER 36 mg extended-release, abuse-deterrent capsule (Xtampza) | 60 capsules per 30 days (QL cumulative across strengths) | B |
| oxycodone ER 40 mg tablet (Oxycontin) | 120 tablets per 30 days (QL cumulative across strengths) | B |
| oxycodone ER 60 mg tablet (Oxycontin) | 120 tablets per 30 days (QL cumulative across strengths) | B |
| oxycodone ER 80 mg tablet (Oxycontin) | 120 tablets per 30 days (QL cumulative across strengths) | B |
| oxycodone ER 9 mg extended-release, abuse-deterrent capsule (Xtampza) | 240 capsules per 30 days (QL cumulative across strengths) | B |
| oxycodone-acetaminophen CR 7.5-325 mg controlled release tablet (Xartemis) | 120 tablets per 30 days (QL cumulative across strengths) | B |
| oxymorphone SR 10 mg sustained-release tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| oxymorphone SR 10 mg sustained-release, crush resistant tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| oxymorphone SR 15 mg sustained-release tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| oxymorphone SR 15 mg sustained-release, crush resistant tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| oxymorphone SR 20 mg sustained-release tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| oxymorphone SR 20 mg sustained-release, crush resistant tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| oxymorphone SR 30 mg sustained-release tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| oxymorphone SR 30 mg sustained-release, crush resistant tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| oxymorphone SR 40 mg sustained-release tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| oxymorphone SR 40 mg sustained-release, crush resistant tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| oxymorphone SR 5 mg sustained-release tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| oxymorphone SR 5 mg sustained-release, crush resistant tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| oxymorphone SR 7.5 mg sustained-release tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | BG |
| oxymorphone SR 7.5 mg sustained-release, crush resistant tablet (Opana ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| paliperidone 1.5 mg tablet (Invega) | 30 tablets per 30 days | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| paliperidone 3 mg tablet (Invega) | 30 tablets per 30 days | BG |
| paliperidone 6 mg tablet (Invega) | 60 tablets per 30 days | BG |
| paliperidone 9 mg tablet (Invega) | 30 tablets per 30 days | BG |
| pantoprazole 20 mg delayed-release tablets (Protonix) | 60 tablets per 30 days (QL cumulative across agents) | BG |
| pantoprazole 40 mg delayed-release oral suspension packets (Protonix) | 60 packets per 30 days (QL cumulative across agents) | B |
| pantoprazole 40 mg delayed-release tablets (Protonix) | 60 tablets per 30 days (QL cumulative across agents) | BG |
| parathyroid hormone 100 mcg subcutaneous injection (Natpara) | 1 package per 28 days (2 cartridges = 1 pkg = 28 doses) | B |
| parathyroid hormone 25 mcg subcutaneous injection (Natpara) | 1 package per 28 days (2 cartridges = 1 pkg = 28 doses) | B |
| parathyroid hormone 50 mcg subcutaneous injection (Natpara) | 1 package per 28 days (2 cartridges = 1 pkg = 28 doses) | B |
| parathyroid hormone 75 mcg subcutaneous injection (Natpara) | 1 package per 28 days (2 cartridges = 1 pkg = 28 doses) | B |
| pasireotide 0.09 mcg/mL SQ injection (Signifor) | 60 mL per 30 days (2 mL = 2 ampules) | B |
| pasireotide 0.3 mcg/mL SQ injection (Signifor) | 60 mL per 30 days (2 mL = 2 ampules) | B |
| pasireotide 0.6 mcg/mL SQ injection (Signifor) | 60 mL per 30 days (2 mL = 2 ampules) | B |
| peginterferon β -1a 125 mcg/0.5mL Autoinjector pen (Plegridy) | 2 pens per 28 days (2 pens = 1 carton) | B |
| peginterferon β -1a 125 mcg/0.5mL prefilled syringe (Plegridy) | 2 syringes per 28 days (2 syringes = 1 carton) | B |
| peginterferon β -1a Starter kit (Plegridy) | 1 kit per 180 days | B |
| pimavanserin 10 mg tablet (Nuplazid) | 30 tablets per 30 days | B |
| pimavanserin 17 mg tablet (Nuplazid) | 60 tablets per 30 days | B |
| pimavanserin 34 mg capsule (Nuplazid) | 30 capsules per 30 days | B |
| pirbuterol 200 mcg/actuation oral inhaler (Maxair Autohaler) | 1 inhaler per 30 days (14 g = 1 inhaler = 400 doses) | B |
| pirfenidone 267 mg capsule (Esbriet) | 180 capsules per 30 days | B |
| pirfenidone 267 mg tablet (Esbriet) | 180 tablets per 30 days | B |
| pirfenidone 801 mg tablet (Esbriet) | 90 tablets per 30 days | B |
| plecanatide 3 mg tablet (Trulance) | 30 tablets per 30 days QL cumulative across agents | B |
| pramlintide 1000 mcg/mL 120-dose pen (Symlin) | 10.8 mL per 30 days (10.8 mL = 2 boxes) | B |
| pramlintide 1000 mcg/mL 60-dose pen (Symlin) | 6 mL per 30 days (6 mL = 2 boxes) | B |
| prednisone, delayed release 1 mg tablet (Rayos) | 30 tablets per 30 days | B |
| prednisone, delayed release 2 mg tablet (Rayos) | 30 tablets per 30 days | B |
| prednisone, delayed release 5 mg tablet (Rayos) | 30 tablets per 30 days | B |
| pregabalin 100 mg capsule (Lyrica) | 90 capsules per 30 days (QL cumulative across strengths) | B |
| pregabalin 150 mg capsule (Lyrica) | 90 capsules per 30 days (QL cumulative across strengths) | B |
| pregabalin 165 mg tablet, extended-release (Lyrica CR) | 30 tablets per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| pregabalin 20 mg/mL oral solution (Lyrica) | 900 mLs per 30 days | B |
| pregabalin 200 mg capsule (Lyrica) | 90 capsules per 30 days (QL cumulative across strengths) | B |
| pregabalin 225 mg capsule (Lyrica) | 90 capsules per 30 days (QL cumulative across strengths) | B |
| pregabalin 25 mg capsule (Lyrica) | 90 capsules per 30 days (QL cumulative across strengths) | B |
| pregabalin 300 mg capsule (Lyrica) | 90 capsules per 30 days (QL cumulative across strengths) | B |
| pregabalin 330 mg tablet, extended-release (Lyrica CR) | 60 tablets per 30 days | B |
| pregabalin 50 mg capsule (Lyrica) | 90 capsules per 30 days (QL cumulative across strengths) | B |
| pregabalin 75 mg capsule (Lyrica) | 90 capsules per 30 days (QL cumulative across strengths) | B |
| pregabalin 82.5 mg tablet, extended-release (Lyrica CR) | 30 tablets per 30 days | B |
| progesterone 4% gel (Crinone) | 60 applicators per 30 days | B |
| progesterone 8% gel (Crinone) | 60 applicators per 30 days | B |
| Progestin Contraceptives all strengths tablets (Progestin Contraceptives) | 28 tablets per 21 days | BG |
| prucalopride 1 mg tablet (Motegrity) | 30 tablets per 30 days QL cumulative across agents | B |
| prucalopride 2 mg tablet (Motegrity) | 30 tablets per 30 days QL cumulative across agents | B |
| quetiapine 100 mg tablet (Seroquel) | 120 tablets per 30 days | BG |
| quetiapine 200 mg tablet (Seroquel) | 90 tablets per 30 days | BG |
| quetiapine 25 mg tablet (Seroquel) | 180 tablets per 30 days | BG |
| quetiapine 300 mg tablet (Seroquel) | 60 tablets per 30 days | BG |
| quetiapine 400 mg tablet (Seroquel) | 60 tablets per 30 days | BG |
| quetiapine 50 mg tablet (Seroquel) | 180 tablets per 30 days | BG |
| quetiapine XR 150 mg extended-release tablet (Seroquel XR) | 30 tablets per 30 days | BG |
| quetiapine XR 200 mg extended-release tablet (Seroquel XR) | 30 tablets per 30 days | BG |
| quetiapine XR 300 mg extended-release tablet (Seroquel XR) | 60 tablets per 30 days | BG |
| quetiapine XR 400 mg extended-release tablet (Seroquel XR) | 60 tablets per 30 days | BG |
| quetiapine XR 50 mg extended-release tablet (Seroquel XR) | 60 tablets per 30 days | BG |
| rabeprazole 10 mg extended-release sprinkle capsule (Aciphex Sprinkle) | 60 tablets per 30 days (QL cumulative across agents) | B |
| rabeprazole 20 mg delayed-release tablets (Aciphex) | 60 tablets per 30 days (QL cumulative across agents) | BG |
| rabeprazole 5 mg extended-release sprinkle capsule (Aciphex Sprinkle) | 60 tablets per 30 days (QL cumulative across agents) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| raltegravir 100 mg chewable tablets (Isentress) | 180 tablets per 30 days | B |
| raltegravir 100 mg packets (Isentress) | 60 packets per 30 days | B |
| raltegravir 25 mg chewable tablets (Isentress) | 180 tablets per 30 days | B |
| raltegravir 400 mg tablets (Isentress) | 60 tablets per 30 days | B |
| raltegravir 600 mg tablets (Isentress HD) | 60 tablets per 30 days | B |
| ramelteon 8 mg tablet (Rozerem) | 30 tablets per 30 days (QL cumulative across agents) | B |
| rifaximin 200 mg tablet (Xifaxan) | 9 tablets per 30 days | B |
| rifaximin 550 mg tablet (Xifaxan) | 60 tablets per 30 days | B |
| rilonacept 220 mg injection (Arcalyst) | 4 vials per 28 days | B |
| rilpivirine 25 mg tablet (Edurant) | 30 tablets per 30 days | B |
| riociguat 0.5 mg tablets (Adempas) | 90 tablets per 30 days | B |
| riociguat 1 mg tablets (Adempas) | 90 tablets per 30 days | B |
| riociguat 1.5 mg tablets (Adempas) | 90 tablets per 30 days | B |
| riociguat 2 mg tablets (Adempas) | 90 tablets per 30 days | B |
| riociguat 2.5 mg tablets (Adempas) | 90 tablets per 30 days | B |
| risankizumab-rzaa 75 mg/0.83 mL prefilled syringe (Skyrizi) | 1 box per 84 days | B |
| risedronate 150 mg tablets (Actonel) | 1 tablets per 30 days | BG |
| risedronate 30 mg tablets (Actonel) | 30 tablets per 30 days | BG |
| risedronate 35 mg delayed-release tablets (Atelvia) | 4 tablets per 28 days (1 pack = 4 tablets) | BG |
| risedronate 35 mg tablets (Actonel) | 4 tablets per 28 days (1 pack = 4 tablets) | BG |
| risedronate 5 mg tablets (Actonel) | 30 tablets per 30 days | BG |
| risperidone 0.25 mg tablet (Risperdal) | 120 tablets per 30 days | BG |
| risperidone 0.5 mg tablet (Risperdal) | 120 tablets per 30 days | BG |
| risperidone 1 mg tablet (Risperdal) | 120 tablets per 30 days | BG |
| risperidone 1 mg/mL oral solution (Risperdal) | 480 mL per 30 days | BG |
| risperidone 2 mg tablet (Risperdal) | 120 tablets per 30 days | BG |
| risperidone 3 mg tablet (Risperdal) | 60 tablets per 30 days | BG |
| risperidone 4 mg tablet (Risperdal) | 120 tablets per 30 days | BG |
| risperidone extended release 120 mg prefilled syringe (Perseris) | 1 syringe per 30 days | B |
| risperidone extended release 90 mg prefilled syringe (Perseris) | 1 syringe per 30 days | B |
| risperidone ODT 0.25 mg orally disintegrating tablets (Risperdal M-Tab) | 60 tablets per 30 days | B |
| risperidone ODT 0.5 mg orally disintegrating tablets (Risperdal M-Tab) | 60 tablets per 30 days | BG |
| risperidone ODT 1 mg orally disintegrating tablets (Risperdal M-Tab) | 60 tablets per 30 days | BG |
| risperidone ODT 2 mg orally disintegrating tablets (Risperdal M-Tab) | 60 tablets per 30 days | BG |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| risperidone ODT 3 mg orally disintegrating tablets (Risperdal M-Tab) | 60 tablets per 30 days | BG |
| risperidone ODT 4 mg orally disintegrating tablets (Risperdal M-Tab) | 120 tablets per 30 days | BG |
| ritonavir 100 mg capsule (Norvir) | 360 capsules per 30 days | B |
| ritonavir 100 mg powder packet (Norvir) | 360 packets per 30 days | B |
| ritonavir 100 mg tablet (Norvir) | 360 tablets per 30 days | BG |
| ritonavir 80 mg/mL oral solution (Norvir) | 480 mL per 30 days (240 mL bottle) | B |
| rivaroxaban 10 mg tablet (Xarelto) | 30 tablets per 30 days | B |
| rivaroxaban 15 mg tablet (Xarelto) | 60 tablets per 30 days | B |
| rivaroxaban 2.5 mg tablet (Xarelto) | 60 tablets per 30 days | B |
| rivaroxaban 20 mg tablet (Xarelto) | 30 tablets per 30 days | B |
| rivaroxaban Starter Pack tablets (Xarelto) | 1 kit per 30 days | B |
| rizatriptan 10 mg tablets (Maxalt) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| rizatriptan 10 mg tablets (Maxalt-MLT) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| rizatriptan 5 mg tablets (Maxalt) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| rizatriptan 5 mg tablets (Maxalt-MLT) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| rolapitant 90 mg tablet (Varubi) | 6 tablets per 30 days | B |
| sacubitril/valsartan 24-26 mg tablet (Entresto) | 60 tablets per 30 days | B |
| sacubitril/valsartan 49-51 mg tablet (Entresto) | 60 tablets per 30 days | B |
| sacubitril/valsartan 97-103 mg tablet (Entresto) | 60 tablets per 30 days | B |
| salmeterol 50 mcg/actuation oral inhaler (Serevent Diskus) | 60 blisters per 30 days (60 blisters = 1 inhaler = 60 doses) | B |
| saquinavir 200 mg hard gel capsule (Invirase) | 300 capsules per 30 days | B |
| saquinavir 500 mg hard gel tablet (Invirase) | 120 tablets per 30 days | B |
| sarilumab 150 mg/1.14 mL pens (Kevzara) | 2 pens per 28 days (2.28 mLs = 2 syringes = 1 box) | B |
| sarilumab 150 mg/1.14 mL prefilled syringe (Kevzara) | 2 syringes per 28 days (2.28 mLs = 2 syringes = 1 box) | B |
| sarilumab 200 mg/1.14 mL pens (Kevzara) | 2 pens per 28 days (2.28 mLs = 2 syringes = 1 box) | B |
| sarilumab 200 mg/1.14 mL prefilled syringe (Kevzara) | 2 syringes per 28 days (2.28 mLs = 2 syringes = 1 box) | B |
| saxagliptin 2.5 mg tablet (Onglyza) | 30 tablets per 30 days | B |
| saxagliptin 5 mg tablet (Onglyza) | 30 tablets per 30 days | B |
| saxagliptin/metformin 2.5-1000 mg tablet (Kombiglyze XR) | 60 tablets per 30 days | B |
| saxagliptin/metformin 5-1000 mg tablet (Kombiglyze XR) | 30 tablets per 30 days | B |
| saxagliptin/metformin 5-500 mg tablet (Kombiglyze XR) | 30 tablets per 30 days | B |
| secukinumab 150 mg/mL autoinjector (Cosentyx) | 1 pen per 28 days | B |
| secukinumab 150 mg/mL autoinjector (Cosentyx) | 2 pens per 28 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| secukinumab 150 mg/mL prefilled syringe (Cosentyx) | 1 syringe per 28 days | B |
| secukinumab 150 mg/mL prefilled syringe (Cosentyx) | 2 syringes per 28 days | B |
| selexipag 1000 mcg tablets (Uptravi) | 60 tablets per 30 days | B |
| selexipag 1200 mcg tablets (Uptravi) | 60 tablets per 30 days | B |
| selexipag 1400 mcg tablets (Uptravi) | 60 tablets per 30 days | B |
| selexipag 1600 mcg tablets (Uptravi) | 60 tablets per 30 days | B |
| selexipag 200 & 800 mcg Therapy Pack (Uptravi) | 1 box per 180 days (200 tablets = 1 box) | B |
| selexipag 200 mcg tablets (Uptravi) | 60 tablets per 30 days | B |
| selexipag 200 mcg tablets, titration pack (Uptravi) | 140 tablets per 180 days | B |
| selexipag 400 mcg tablets (Uptravi) | 60 tablets per 30 days | B |
| selexipag 600 mcg tablets (Uptravi) | 60 tablets per 30 days | B |
| selexipag 800 mcg tablets (Uptravi) | 60 tablets per 30 days | B |
| semaglutide 2 mg/1.5mL prefilled pen (Ozempic) | 1 pen per 28 days (1.5 mLs = 1 pen) | B |
| semaglutide 2 mg/1.5mL prefilled pen (Ozempic) | 2 pens per 28 days (3 mLs = 2 pens) | B |
| sildenafil 10 mg/mL suspension (Revatio) | 2 bottles per 30 days (1 bottle = 112 mLs) | B |
| sildenafil 100 mg tablets (Viagra) | 8 tablets per 30 days (QL cumulative across agents) | BG |
| sildenafil 20 mg tablets (Revatio) | 90 tablets per 30 days | BG |
| sildenafil 25 mg tablets (Viagra) | 8 tablets per 30 days (QL cumulative across agents) | BG |
| sildenafil 50 mg tablets (Viagra) | 8 tablets per 30 days (QL cumulative across agents) | BG |
| siponimod 0.25 mg tablet (Mayzent) | 120 tablets per 30 days | B |
| siponimod 0.25 mg tablet, starter pak (Mayzent) | 1 pack per 180 days | B |
| siponimod 2 mg tablet (Mayzent) | 30 tablets per 30 days | B |
| sitagliptin 100 mg tablet (Januvia) | 30 tablets per 30 days | B |
| sitagliptin 25 mg tablet (Januvia) | 30 tablets per 30 days | B |
| sitagliptin 50 mg tablet (Januvia) | 30 tablets per 30 days | B |
| sitagliptin/metformin 100-1000 mg extended-release tablet (Janumet XR) | 30 tablets per 30 days | B |
| sitagliptin/metformin 50-1000 mg extended-release tablet (Janumet XR) | 60 tablets per 30 days | B |
| sitagliptin/metformin 50-1000 mg tablet (Janumet) | 60 tablets per 30 days | B |
| sitagliptin/metformin 50-500 mg extended-release tablet (Janumet XR) | 30 tablets per 30 days | B |
| sitagliptin/metformin 50-500 mg tablet (Janumet) | 60 tablets per 30 days | B |
| sitagliptin/simvastatin 100-10 mg tablet (Juvissync) | 30 tablets per 30 days | B |
| sitagliptin/simvastatin 100-20 mg tablet (Juvissync) | 30 tablets per 30 days | B |
| sitagliptin/simvastatin 100-40 mg tablet (Juvissync) | 30 tablets per 30 days | B |
| sitagliptin/simvastatin 50-10 mg tablet (Juvissync) | 30 tablets per 30 days | B |
| sitagliptin/simvastatin 50-20 mg tablet (Juvissync) | 30 tablets per 30 days | B |
| sitagliptin/simvastatin 50-40 mg tablet (Juvissync) | 30 tablets per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| sodium oxybate 500 mg/mL oral solution (Xyrem) | 540 mL per 30 days | B |
| stavudine 1 mg/mL oral solution (Zerit) | 2400 mLs per 30 days | B |
| stavudine 15 mg capsule (Zerit) | 60 capsules per 30 days | BG |
| stavudine 20 mg capsule (Zerit) | 60 capsules per 30 days | BG |
| stavudine 30 mg capsule (Zerit) | 60 capsules per 30 days | BG |
| stavudine 40 mg capsule (Zerit) | 60 capsules per 30 days | BG |
| sucalfate 1 g/10 mL suspension (Carafate) | 1200 mL per 30 days | B |
| sumatriptan 100 mg tablets (Imitrex) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| sumatriptan 11 mg nasal powder (Onzetra Xsail) | 16 doses per 30 days | B |
| sumatriptan 20 mg nasal spray (Imitrex) | 12 doses per 30 days | BG |
| sumatriptan 25 mg tablets (Imitrex) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| sumatriptan 3 mg/0.5 mL auto-injector (Zembrace SymTouch) | 24 doses per 30 days | B |
| sumatriptan 4 mg STATdose (Imitrex) | 12 doses per 30 days | B |
| sumatriptan 4 mg STATdose refill (Imitrex) | 12 doses per 30 days | B |
| sumatriptan 4 mg/0.5 mL single-dose injection device (Sumavel DosePro) | 12 doses per 30 days | B |
| sumatriptan 4 mg/0.5 mL single-dose injection vial (Imitrex) | 12 doses per 30 days | B |
| sumatriptan 5 mg nasal spray (Imitrex) | 12 doses per 30 days | BG |
| sumatriptan 50 mg tablets (Imitrex) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| sumatriptan 6 mg autoinjector pen (Sumatriptan) | 12 doses per 30 days | G |
| sumatriptan 6 mg STATdose (Imitrex) | 12 doses per 30 days | BG |
| sumatriptan 6 mg STATdose refill (Imitrex) | 12 doses per 30 days | B |
| sumatriptan 6 mg/0.5 mg single-dose injection device (Sumavel DosePro) | 12 doses per 30 days | B |
| sumatriptan 6 mg/0.5 mL single-dose injection syringe (Imitrex) | 12 doses per 30 days | B |
| sumatriptan 6 mg/0.5 mL single-dose injection vial (Imitrex) | 12 doses per 30 days | BG |
| sumatriptan 6.5 mg/4h transdermal system (Zecuity) | 12 patches per 30 days | B |
| sumatriptan/naproxen 10 mg/60 mg tablet (Treximet) | 18 tablets per 30 days | B |
| sumatriptan/naproxen 85-500 mg tablets (Treximet) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| suvorexant 10 mg tablet (Belsomra) | 30 tablets per 30 days (QL cumulative across agents) | B |
| suvorexant 15 mg tablet (Belsomra) | 30 tablets per 30 days (QL cumulative across agents) | B |
| suvorexant 20 mg tablet (Belsomra) | 30 tablets per 30 days (QL cumulative across agents) | B |
| suvorexant 5 mg tablet (Belsomra) | 30 tablets per 30 days (QL cumulative across agents) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|---|--|
| tadalafil 10 mg tablets (Cialis) | 8 tablets per 30 days (QL cumulative across agents) | BG |
| tadalafil 2.5 mg tablets (Cialis) | 30 tablets per 30 days | BG |
| tadalafil 20 mg tablets (Adcirca) | 60 tablets per 30 days | BG |
| tadalafil 20 mg tablets (Cialis) | 8 tablets per 30 days (QL cumulative across agents) | BG |
| tadalafil 5 mg tablets (Cialis) | 30 tablets per 30 days | BG |
| tafluprost 0.0015% ophthalmic solution (Zioptan) | 30 vials per 30 days | B |
| tapentadol 100 mg extended-release tablet (Nucynta ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| tapentadol 100 mg tablets (Nucynta) | 180 tablets per 30 days (QL cumulative across strengths) | B |
| tapentadol 150 mg extended-release tablet (Nucynta ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| tapentadol 200 mg extended-release tablet (Nucynta ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| tapentadol 250 mg extended-release tablet (Nucynta ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| tapentadol 50 mg extended-release tablet (Nucynta ER) | 60 tablets per 30 days (QL cumulative across strengths) | B |
| tapentadol 50 mg tablets (Nucynta) | 180 tablets per 30 days (QL cumulative across strengths) | B |
| tapentadol 75 mg tablets (Nucynta) | 180 tablets per 30 days (QL cumulative across strengths) | B |
| tasimelteon 20 mg capsule (Hetlioz) | 30 capsules per 30 days | B |
| tavaborole 5% solution (Kerydin) | 4 mLs per 30 days | B |
| tedizolid 200 mg tablets (Sivextro) | 6 tablets per 180 days | B |
| tenofovir 150 mg tablet (Viread) | 30 tablets per 30 days | B |
| tenofovir 200 mg tablet (Viread) | 30 tablets per 30 days | B |
| tenofovir 250 mg tablet (Viread) | 30 tablets per 30 days | B |
| tenofovir 300 mg tablet (Viread) | 30 tablets per 30 days | BG |
| tenofovir 40 mg/1 gram oral powder for reconstitution (Viread) | 240 grams per 30 days | B |
| teriflunomide 14 mg tablet (Aubagio) | 30 tablets per 30 days | B |
| teriflunomide 7 mg tablet (Aubagio) | 30 tablets per 30 days | B |
| teriparatide 250 mcg/mL injection (Forteo) | 1 injection per 28 days (2.4 mL = 1 injection) | B |
| tesamoralin 1 mg vials, subcutaneous (Egrifta) | 1 kit per 30 days (60 vials = 1 kit) | B |
| tesamoralin 2 mg vials, subcutaneous (Egrifta) | 1 kit per 30 days (30 vials = 1 kit) | B |
| testosterone 1% gel, 2 x 75 g pump (Androgel) | 300 grams per 30 days | BG |
| testosterone 1% gel, 2.5 g packet (Androgel) | 60 packets per 30 days (150 grams = 60 packets) | BG |
| testosterone 1% gel, 2.5 g packet (Bio-T-Gel) | 60 packets per 30 days (150 grams = 60 packets) | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| testosterone 1% gel, 5 g packet (Androgel) | 60 packets per 30 days (300 grams = 60 packets) | BG |
| testosterone 1% gel, 5 g packet (Bio-T-Gel) | 60 packets per 30 days (300 grams = 60 packets) | B |
| testosterone 1% gel, 5 g packet (Vogelxo/Testosterone) | 300 grams per 30 days | B |
| testosterone 1% gel, 5 g tube (Testim/Testosterone) | 300 grams per 30 days | BG |
| testosterone 1% gel, 75 g pump (Vogelxo/Testosterone) | 300 grams per 30 days | B |
| testosterone 1.62% gel, 1.25 g packet (Androgel) | 30 packets per 30 days (37.5 grams = 30 packets) | BG |
| testosterone 1.62% gel, 2.5 g packet (Androgel) | 60 packets per 30 days (150 grams = 60 packets) | BG |
| testosterone 1.62% gel, 75 g pump (Androgel) | 150 grams per 30 days | BG |
| testosterone 2% gel, 60 g pump (Fortesta) | 120 grams per 30 days | BG |
| testosterone 2% ointment, 60 g jar (First - Testosterone) | 60 grams per 30 days | B |
| testosterone 2 mg/day transdermal system (Androderm) | 30 patches per 30 days | B |
| testosterone 30 mg/1.5 mL solution, 90 mL pump (Axiron) | 180 mL per 30 days | BG |
| testosterone 4 mg/day transdermal system (Androderm) | 30 patches per 30 days | B |
| testosterone 5.5 mg/actuation nasal gel, 7.32 g dispenser (Natesto) | 3 dispensers per 30 days (1 dispenser = 7.32 grams) | B |
| testosterone 75 mg pellets (Testopel) | 6 pellets per 90 days | B |
| testosterone buccal system 30 mg buccal system (Striant) | 60 systems per 30 days | B |
| testosterone cream 2% cream, 60 g jar (First - Testosterone MC) | 60 grams per 30 days | B |
| testosterone cypionate 100 mg/mL intramuscular oil, 10 mL multiple dose vial (Depo-Testosterone) | 10 mL per 28 days | BG |
| testosterone cypionate 200 mg/mL intramuscular oil, 1 mL vials (Depo-Testosterone) | 10 vials per 28 days | BG |
| testosterone cypionate 200 mg/mL intramuscular oil, 10 mL multiple dose vial (Depo-Testosterone) | 1 vial per 28 days | BG |
| testosterone enanthate 100 mg/0.5 mL auto-injector (Xyosted) | 4 pens per 28 days | B |
| testosterone enanthate 200 mg/mL intramuscular oil, 5 mL multiple dose vial (Delatestryl) | 5 mL per 28 days (brand drug has been discontinued by mfg, but may still be available) | BG |
| testosterone enanthate 50 mg/0.5 mL auto-injector (Xyosted) | 4 pens per 28 days | B |
| testosterone enanthate 75 mg/0.5 mL auto-injector (Xyosted) | 4 pens per 28 days | B |
| testosterone undecanoate 750 mg/3mL oil for IM injection (Aveed) | 3 mL per 28 days (3 mL = 1 vial) | B |
| tiotropium 1.25 mcg/actuation oral inhaler (Spiriva Respimat) | 1 inhaler per 30 days (4 grams = 1 inhaler) | B |
| tiotropium 18 mcg/actuation oral inhaler (Spiriva Handihaler) | 30 capsules per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| tiotropium 2.5 mcg/actuation oral inhaler (Spiriva Respimat) | 1 inhaler per 30 days (4 grams = 1 inhaler) | B |
| tiotropium/olodaterol 2.5 mcg/actuation oral inhaler (Stiolto Respimat) | 1 cartridge per 30 days (4 grams = 1 cartridge) | B |
| tipranavir 100 mg/mL oral solution (Aptivus) | 390 mLs per 30 days | B |
| tipranavir 250 mg capsule (Aptivus) | 120 capsules per 30 days | B |
| tizanidine 2 mg capsules (Zanaflex) | 180 capsules per 30 days | BG |
| tizanidine 2 mg tablets (Zanaflex) | 180 tablets per 30 days | BG |
| tizanidine 4 mg capsules (Zanaflex) | 180 capsules per 30 days | BG |
| tizanidine 4 mg tablets (Zanaflex) | 180 tablets per 30 days | BG |
| tizanidine 6 mg capsules (Zanaflex) | 180 capsules per 30 days | BG |
| tobramycin 28 mg inhalation capsule (Tobi Podhaler) | 224 capsules per 56 days | B |
| tobramycin 300 mg/4 mL inhalation ampules (Bethkis) | 224 mL per 56 days (224 mL = 56 ampules) | B |
| tobramycin 300 mg/5 mL inhalation nebulas (Kitabis Pak) | 280 mL per 56 days (280 mL = 56 ampules) | B |
| tobramycin 300 mg/5 mL inhalation ampules (Tobi) | 280 mL per 56 days (280 mL = 56 ampules) | BG |
| tocilizumab 162 mg/0.9 ml autoinjector (Actemra) | 4 pens per 28 days | B |
| tocilizumab 162 mg/0.9 ml syringe (Actemra) | 4 syringes per 28 days | B |
| tofacitinib 10 mg tablet (Xeljanz) | 60 tablets per 30 days | B |
| tofacitinib 11 mg tablet (Xeljanz XR) | 30 tablets per 30 days | B |
| tofacitinib 5 mg tablet (Xeljanz) | 60 tablets per 30 days | B |
| tolvaptan 15 mg tablet (Jynarque) | 60 tablets per 30 days | B |
| tolvaptan 15 mg tablets (Samsca) | 30 tablet per 365 days | B |
| tolvaptan 30 mg tablet (Jynarque) | 30 tablets per 30 days | B |
| tolvaptan 30 mg tablets (Samsca) | 60 tablets per 365 days | B |
| tolvaptan 45-15 mg tablets, therapy pack (Jynarque) | 56 tablets per 28 days | B |
| tolvaptan 60-30 mg tablets, therapy pack (Jynarque) | 56 tablets per 28 days | B |
| tolvaptan 90-30 mg tablets, therapy pack (Jynarque) | 56 tablets per 28 days | B |
| topiramate extended-release 100 mg capsule (Qudexy XR) | 30 capsules per 30 days | B |
| topiramate extended-release 100 mg capsule (Topiramate ER) | 30 capsules per 30 days | B |
| topiramate extended-release 100 mg capsule (Trokendi XR) | 30 capsules per 30 days | B |
| topiramate extended-release 150 mg capsule (Qudexy XR) | 30 capsules per 30 days | B |
| topiramate extended-release 150 mg capsule (Topiramate ER) | 30 capsules per 30 days | B |
| topiramate extended-release 200 mg capsule (Qudexy XR) | 60 capsules per 30 days | B |
| topiramate extended-release 200 mg capsule (Topiramate ER) | 60 capsules per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|--|--|--|
| topiramate extended-release 200 mg capsule (Trokendi XR) | 60 capsules per 30 days | B |
| topiramate extended-release 25 mg capsule (Qudexy XR) | 30 capsules per 30 days | B |
| topiramate extended-release 25 mg capsule (Topiramate ER) | 30 capsules per 30 days | B |
| topiramate extended-release 25 mg capsule (Trokendi XR) | 30 capsules per 30 days | B |
| topiramate extended-release 50 mg capsule (Qudexy XR) | 30 capsules per 30 days | B |
| topiramate extended-release 50 mg capsule (Topiramate ER) | 30 capsules per 30 days | B |
| topiramate extended-release 50 mg capsule (Trokendi XR) | 30 capsules per 30 days | B |
| tramadol 100 mg sustained-release tablet (Ryzolt) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| tramadol 100 mg sustained-release tablet (Ultram ER) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| tramadol 200 mg sustained-release tablet (Ryzolt) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| tramadol 200 mg sustained-release tablet (Ultram ER) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| tramadol 300 mg sustained-release tablet (Ryzolt) | 30 tablets per 30 days (QL cumulative across strengths) | B |
| tramadol 300 mg sustained-release tablet (Ultram ER) | 30 tablets per 30 days (QL cumulative across strengths) | BG |
| tramadol 50 mg tablet (Ultram) | 240 tablets per 30 days | BG |
| tramadol ER 100 mg sustained-release capsule (Conzip) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| tramadol ER 150 mg sustained-release capsule (Tramadol ER) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| tramadol ER 200 mg sustained-release capsule (Conzip) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| tramadol ER 300 mg sustained-release capsule (Conzip) | 30 capsules per 30 days (QL cumulative across strengths) | B |
| travoprost 0.004% ophthalmic solution (Travatan Z) | 2.5 mL per 20 days | B |
| travoprost 0.004% ophthalmic solution (Travoprost) | 2.5 mL per 20 days | B |
| treprostinil 0.125 mg tablets (Orenitram) | 300 tablets per 30 days | B |
| treprostinil 0.25 mg tablets (Orenitram) | 300 tablets per 30 days | B |
| treprostinil 0.6 mg/mL solution for inhalation, 4 pack carton (Tyvaso) | 7 packages per 28 days (1 package = 4 ampules = 11.6mLs) | B |
| treprostinil 0.6 mg/mL solution for inhalation, Refill Kit (Tyvaso) | 1 package per 28 days (1 package = 81.2 mLs) | B |
| treprostinil 0.6 mg/mL solution for inhalation, Starter Kit (Tyvaso) | 1 kit per 180 days (1 kit = 81.2 mLs) | B |
| treprostinil 1 mg tablets (Orenitram) | 300 tablets per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|---|--|
| treprostinil 2.5 mg tablets (Orenitram) | 300 tablets per 30 days | B |
| treprostinil 5 mg tablets (Orenitram) | 300 tablets per 30 days | B |
| triamcinolone 55 mcg/actuation nasal spray (Nasacort AQ) | 1 inhaler per 30 days (16.5 g = 1 bottle = 120 doses) | BG |
| ulipristal 30 mg tablets (Ella) | 2 tablets per 365 days | B |
| umeclidinium - vilanterol 62.5-25 mcg/inhalation oral inhaler (Anoro Ellipta) | 1 inhaler per 30 days (60 blisters = 1 inhaler = 30 doses) | B |
| umeclidinium 62.5 mcg/actuation oral inhaler (Incruse Ellipta) | 1 inhaler per 30 days (30 blisters = 1 inhaler) | B |
| unoprostone 0.15% ophthalmic solution (Rescula) | 5 mL per 30 days | B |
| urofollitropin 75 unit injection (Bravelle) | 60 vials per 30 days | B |
| ustekinumab 45 mg/0.5 mL syringe (Stelara) | 1 syringe per 84 days | B |
| ustekinumab 90 mg/1 mL syringe (Stelara) | 1 syringe per 56 days | B |
| valbenazine 40 mg capsule (Ingrezza) | 30 capsules per 30 days | B |
| valbenazine 80 mg capsule (Ingrezza) | 30 capsules per 30 days | B |
| varденаfil 10 mg orally disintegrating tablets (Staxyn) | 8 tablets per 30 days (QL cumulative across agents) | BG |
| varденаfil 10 mg tablets (Levitra) | 8 tablets per 30 days (QL cumulative across agents) | BG |
| varденаfil 2.5 mg tablets (Levitra) | 8 tablets per 30 days (QL cumulative across agents) | BG |
| varденаfil 20 mg tablets (Levitra) | 8 tablets per 30 days (QL cumulative across agents) | BG |
| varденаfil 5 mg tablets (Levitra) | 8 tablets per 30 days (QL cumulative across agents) | BG |
| vedolizumab 300 mg vial (Entyvio) | 1 vial per 56 days | B |
| zaleplon 10 mg capsule (Sonata) | 30 capsules per 30 days (QL cumulative across agents) | BG |
| zaleplon 5 mg capsule (Sonata) | 30 capsules per 30 days (QL cumulative across agents) | BG |
| zanamivir 5 mg/blister diskhaler (Relenza) | 20 disks per 120 days | B |
| zidovudine 10 mg/mL syrup (Retrovir) | 1920 mLs per 30 days | BG |
| zidovudine 100 mg capsule (Retrovir) | 180 capsules per 30 days | BG |
| zidovudine 300 mg tablet (Retrovir) | 60 tablets per 30 days | G |
| ziprasidone 20 mg capsule (Geodon) | 60 capsules per 30 days | BG |
| ziprasidone 40 mg capsule (Geodon) | 60 capsules per 30 days | BG |
| ziprasidone 60 mg capsule (Geodon) | 60 capsules per 30 days | BG |
| ziprasidone 80 mg capsule (Geodon) | 60 capsules per 30 days | BG |
| zolmitriptan 2.5 mg tablets (Zomig ZMT) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| zolmitriptan 2.5 mg tablets (Zomig) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| zolmitriptan 2.5 mg/100 microliters nasal spray (Zomig) | 12 doses per 30 days | B |

| Drug (generic) strength | Dispensing Limit | Generic and Brand (BG), Brand Only (B), Generic only (G) |
|---|--|--|
| zolmitriptan 5 mg tablets (Zomig ZMT) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| zolmitriptan 5 mg tablets (Zomig) | 18 tablets per 30 days (QL cumulative across tablets) | BG |
| zolmitriptan 5 mg/100 microliters nasal spray (Zomig) | 12 doses per 30 days | B |
| zolpidem 1.75 mg sublingual tablet (Intermezzo) | 30 tablets per 30 days (QL cumulative across agents) | BG |
| zolpidem 10 mg orally disintegrating tablets (Eduar) | 30 tablets per 30 days (QL cumulative across agents) | B |
| zolpidem 10 mg tablet (Ambien) | 30 tablets per 30 days (QL cumulative across agents) | BG |
| zolpidem 12.5 mg extended-release tablet (Ambien CR) | 30 tablets per 30 days (QL cumulative across agents) | BG |
| zolpidem 3.5 mg sublingual tablet (Intermezzo) | 30 tablets per 30 days (QL cumulative across agents) | B |
| zolpidem 5 mg orally disintegrating tablets (Eduar) | 30 tablets per 30 days (QL cumulative across agents) | B |
| zolpidem 5 mg tablet (Ambien) | 30 tablets per 30 days (QL cumulative across agents) | BG |
| zolpidem 5 mg/actuation oral spray (Zolpimist) | 7.7 mL per 30 days (7.7 mL = 1 cannister = 60 doses) | B |
| zolpidem 6.25 mg extended-release tablet (Ambien CR) | 30 tablets per 30 days (QL cumulative across agents) | BG |